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General introduction and outline
1The autonomic nervous system (ANS) controls homeostasis and regulates visceral func-tions. ANS function is impaired in obesity, diabetes and cardiovascular disease. However, 
it is yet unclear whether this impairment is merely a consequence of underlying disease, 
or may also be involved in the development of disease. The main objective of this thesis 
was to study the role of ANS function in the development of diabetes and cardiovascular 
disease. This general introduction describes the current state of knowledge about ANS 
function and its role in health and disease. It furthermore describes the outline of this 
thesis and summarizes the studies and data that were used.
THE AUTONOMIC NERVOUS SYSTEM
Most functions of the ANS are not in conscious control, and are based on feedback loops 
and reflexes. The central part of the ANS is located in the medulla oblongata of the brain-
stem and the hypothalamus.1 Afferent nerves convey information from organs, muscles, 
the limbic system, the circulatory system and sensory organs to the central part of the 
ANS. The efferent pathways consist of the parasympathetic and the sympathetic nervous 
system, which have mostly opposite effects on organs.2 The functions of the parasympa-
thetic and the sympathetic nervous system are illustrated in the Figure. The sympathetic 
nervous system is predominant in active situations, ranging from small actions such as 
posture changes to “flight-fight-or-fright” actions. The parasympathetic nervous system 
is predominant during periods of lower activity, in most individuals this is the larger 
part of the day. The sympathetic output originates from the ventrolateral medulla in the 




brain stem and is effectuated through sympathetic preganglionic neurons located in the 
spinal cord at the T1-L2 segments. The parasympathetic output also originates from the 
brainstem (nucleus ambiguus) and is effectuated through cranial nerves (CN3, CN7, CN9, 
CN10) and the spinal cord at the S2-4 segments.2 The most important neurotransmit-
ters in the efferent part of the ANS are norepinephrine for sympathetic transmission 
and acetylcholine for parasympathetic transmission.2 The function of the ANS can be 
measured in several ways. Often, autonomic control of the cardiovascular system is used 
to estimate ANS function.
AUTONOMIC CONTROL OF THE CARDIOVASCULAR SYSTEM
The cardiovascular system consists of the heart and peripheral vasculature, and its 
purpose is to provide an adequate flow of blood and nutrients to the organs.3 The heart 
is innervated by the parasympathetic nervous system via the vagal nerve and by the 
sympathetic nervous system via nerves arising from the upper thoracic region of the 
spinal cord. Baroreflexes buffer blood pressure, and thereby play a central role in the 
autonomic regulation of the cardiovascular system. Baroreceptors are not directly sensi-
tive to blood pressure, but rather to the mechanical deformation of the nerve endings 
during stretching of the vascular wall. Two types of baroreceptors can be distinguished. 
Cardiopulmonary baroreceptors are localized in the heart, vena cava, and pulmonary 
vasculature and respond to changes in central venous pressure, whereas arterial baro-
receptors in the aortic arch and carotid sinuses respond to changes in arterial pressure. 
When venous return and arterial blood pressure increase, the sympathetic outflow to 
the heart and peripheral vasculature is inhibited and the parasympathetic outflow is 
stimulated, resulting in a decreased peripheral resistance and decreased heart rate.4 
A decrease in venous return and arterial blood pressure results in more sympathetic 
outflow, decreased parasympathetic outflow, an increase in peripheral resistance and 
an increase in heart rate. Changes in blood pressure are caused by an adjustment in 
peripheral resistance rather than by changes in heart rate.
THE AUTONOMIC NERVOUS SYSTEM IN HEALTH AND DISEASE
In healthy individuals, there is modulation in the sympathetic and parasympathetic 
outflow influenced by the level of activity. This modulation is necessary for an optimal 
control of homeostasis and visceral functions and is a manifestation of adaptivity. 
Impaired ANS function is characterized by reduced modulation in sympathetic and 
parasympathetic outflow, chronic overactivation of the sympathetic nervous system 
13
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1and chronic decreased activation of the parasympathetic nervous system. Impaired ANS function has been associated with obesity, diabetes and cardiovascular disease.
Obesity
Historically, two hypotheses on the association between ANS function and obesity were 
postulated. The first hypothesis stated that low activity of the sympathetic nervous 
system caused weight gain, and the second proposed that activation of the sympathetic 
nervous system and decreased activity of the parasympathetic nervous system were a 
result of obesity.5, 6 The latter hypothesis was adopted by most contemporary research-
ers and is strongly supported by intervention studies on weight loss, showing that after 
a decrease in the amount of body fat by a hypocaloric diet or exercise training, activity 
of the sympathetic nervous system attenuated.7-13
Several epidemiological studies have shown inverse associations between body 
fat and ANS function, and positive associations between body fat and sympathetic 
nervous system activation.14-22 However, only few studies were able to investigate the 
associations between various types of fat, for example visceral fat accumulation within 
the abdomen, and ANS function. A mechanism underlying of the association between 
visceral fat and activation of the sympathetic nervous system may be the production 
of adipocyte derived cytokines (adipokines). Adipocytes, or macrophages invading 
the adipose tissue, secrete several adipokines.23 Visceral fat has a higher secretion rate 
of pro-inflammatory cytokines than subcutaneous fat and inhibits the secretion of 
anti-inflammatory factors.24-27 These cytokines can either directly stimulate the central 
nervous system, by crossing the blood-brain-barrier, or induce low-grade inflammation, 
resulting in sympathetic activation.23, 28 Previous studies have shown that visceral fat is 
stronger associated with cardiovascular risk factors and endpoints than other types of 
body fat.29-32 It is, however, unknown whether visceral fat may also stronger influence 
sympathetic activation than other types of body fat.
Insulin resistance and type 2 diabetes mellitus
Impaired ANS function is a well-known complication of type 2 diabetes mellitus.33, 34 High 
blood glucose and insulin levels and an abundance of advanced glycation endproducts 
can directly damage the nerves or interfere with chemical signalling. Impairment of the 
ANS worsens with the duration of type 2 diabetes, and is associated with an increased 
mortality risk.35 However, several research findings have become known supporting the 
notion that impaired ANS function may not only be a complication of type 2 diabetes, 
but may also be involved in the development of the disease. The ANS innervates several 
organs involved in the glucose metabolism, such as the liver, pancreas, adrenal and skel-
etal muscles. The parasympathetic branch of the ANS seems responsible for the insulin 
Chapter1
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sensitivity of several organs.36 The decreased parasympathetic outflow in impaired ANS 
function may therefore play a role in the development of type 2 diabetes. Moreover, 
non-diabetic offspring of type 2 diabetes patients, who are at high risk of developing 
type 2 diabetes, have a worse ANS function than individuals of the same age without 
a family history of type 2 diabetes, independent of other risk factors.37 Together, these 
arguments suggest that impaired ANS function may not only be a complication of type 
2 diabetes, but may also play a role in the development of the disease.
ANS function has been extensively studied in relation with insulin resistance and 
glucose tolerance. Several cross-sectional studies have shown an inverse association 
between ANS function and insulin resistance and a positive association between ANS 
function and glucose tolerance. Insulin resistance, a subclinical stage of type 2 diabetes, 
is defined as an inadequate response by insulin target tissues to the physiologic effects 
of circulating insulin. The decreased sensitivity to insulin results in compensatory hyper-
insulinaemia. Without this compensation, impaired glucose tolerance or type 2 diabetes 
mellitus may develop.44, 45 Therefore, these previously mentioned studies suggest that 
ANS function is involved in the pathogenesis of type 2 diabetes.38-43 However, because 
of the cross-sectional nature of these studies, the direction of the association remains 
undetermined and it is yet unclear whether impaired ANS function is indeed involved in 
the development of type 2 diabetes.
Cardiovascular disease
An association between ANS function and cardiovascular disease has frequently been 
reported. In 1978, an inverse association between variability in heart rate and mortality 
in patients admitted to the hospital with acute myocardial infarction was first reported.46 
Later studies showed that low baroreflex sensitivity and low heart rate variability were 
risk factors for cardiovascular events, including myocardial infarction,47, 48 heart failure,49 
and atrial fibrillation50 in populations with pre-existing cardiovascular disease. However, 
in these populations impaired ANS function may have been a result of the pre-existing 
cardiovascular abnormalities. Therefore, based on existing studies it remains unclear 
whether impaired ANS function is also a risk factor for the development of cardiovas-
cular disease.
A mechanism underlying the association between impaired ANS function and car-
diovascular disease may be an altered lipid metabolism. Experimental studies in rats 
showed that sympathetic denervation in the liver decreased both hepatic lipogenesis 
and hepatic secretion of very low density lipoprotein (VLDL).51, 52 This indicates that 
sympathetic activation to the liver stimulates lipogenesis and the secretion of VLDL-
triglycerides. Furthermore, in adipose tissue, stimulation of the sympathetic nervous 
15
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1system induces lipolysis, thereby increasing the amount of glycerol and free fatty acids in the circulation.53 Previous epidemiological studies have reported an association of 
sympathetic activation with fasting lipid levels in the circulation.54-56 However, since 
most individuals are in a postprandial state for the larger part of the day, elevated post-
prandial serum triglyceride concentrations may be more important for cardiovascular 
risk.57, 58 Furthermore, in addition to an increased concentration of lipids in the circula-
tion, activation of the SNS may also result in accumulation of lipids in the liver.59 The 
associations of sympathetic activation with postprandial triglyceride concentrations 
and intrahepatic triglyceride content have not been reported yet.
AIM AND OUTLINE OF THIS THESIS
Although the associations between impaired ANS function, obesity, diabetes and 
cardiovascular disease have been investigated in previous studies, it remains unclear 
whether an impaired ANS function is merely a consequence of pre-existing disease, or 
may also be involved in the development of diabetic and cardiovascular disease. The 
aim of this thesis was therefore to study the role of ANS function in the development of 
diabetes and cardiovascular disease.
In chapter 2 we investigated the association between body fat and ANS function. Since 
the role of various fat depots has not been unravelled yet, we studied several types of 
body fat, including abdominal visceral and subcutaneous fat.
In chapter 3 we investigated whether ANS function is a risk factor for type 2 diabetes. 
In order to gain more information on the direction of the association we used follow-up 
data of individuals without diabetes who had been followed until the occurrence of type 
2 diabetes. In chapter 4 we aimed to unravel the interrelationships between body fat, 
ANS function and insulin resistance.
To investigate whether impaired ANS function is a risk factor for the development of car-
diovascular disease, we performed a meta-analysis and meta-regression of prospective 
studies investigating this association in populations without pre-existing cardiovascular 
disease in chapter 5. We hypothesized that an altered lipid metabolism is a mechanism 
underlying the association between impaired ANS function and cardiovascular disease 
and investigated the association between impaired ANS function and alterations in lipid 
metabolism in chapter 6.
Chapter1
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STUDY DESIGNS AND DATA USED IN THIS THESIS
The NEO study
The Netherlands Epidemiology of Obesity (NEO) study is a population-based prospective 
cohort study in 6673 individuals aged 45 to 65 years, with an oversampling of individuals 
with a BMI ≥ 27 kg/m², who were included between September 2008 and October 2012. 
At baseline, participants completed questionnaires for demographic, lifestyle, and clini-
cal information and underwent an extensive physical examination. Random subsamples 
of the study population underwent magnetic resonance imaging (MRI) of the abdomen 
and magnetic resonance spectroscopy of the liver (n=2580), MRI of the heart (n=1207), 
or were equipped with an Actiheart®, a combined heart rate monitor and accelerometer 
(CamNtech Ltd, U.K.) for four days (n=955). To answer the research questions in chapters 
2, 4, and 6 of this thesis, we used the baseline measurements of the NEO study.
The Hoorn study
For the research question in chapter 3 we used data from the Hoorn study, a prospec-
tive cohort study including 2484 adults aged 50 to 75 years from the town of Hoorn, the 
Netherlands. Baseline data were collected between 1989 and 1991 and included data 
on demographic characteristics, medical history, physical activity and a physical exami-
nation. In a subsample of participants (n=631) ANS function was measured. Follow-up 
examinations were performed in 1996-1998 and 2000-2001.
MEASUREMENT OF AUTONOMIC NERVOUS SYSTEM FUNCTION
Unfortunately, a gold standard for assessing activity of the ANS is lacking. Over the past 
decennia, several techniques have been developed. The main measures are described 
below and summarized in the Table.
Microneurography uses fine electrodes that are inserted percutaneously in the nerves to 
record bursts of activity. Often, the easily accessible common peroneal nerve is used to 
measure the efferent postganglionic muscle sympathetic nerve activity.60 Muscle sym-
pathetic nerve activity is a direct measure of sympathetic activity, but it is invasive and 
can only be used on superficial nerves as nerves to internal organs are not accessible.
Catecholamines are sympathetic neurotransmitters which can be measured to estimate 
sympathetic nervous system function.61 Dopamine acts mainly in the central nervous sys-
tem, while epinephrine and norepinephrine mostly have peripheral effects. Epinephrine is 
exclusively produced by the adrenal medulla, whereas norepinephrine is mainly produced 
17
























































































































































































































































































































































































































































































































































































































































































































































by sympathetic postganglionic fibres and is therefore more specific to estimate activity of 
the sympathetic nervous system.62 Norepinephrine can be measured both in urine or in 
plasma. All norepinephrine that is formed by the body is eventually excreted in the urine 
either unchanged or as a metabolite.63 Therefore, total urinary excretion of norepineph-
rine or its metabolites can be used to estimate the synthesis rate of norepinephrine.64, 65 
Measurement of plasma norepinephrine is less straightforward, because it depends not 
only on the release of norepinephrine to plasma, but also on the clearance from the cir-
culation.66, 67 Spill-over techniques aim to solve this problem. Highly specific radiolabelled 
norepinephrine is infused into the plasma at a constant rate to reach steady-state condi-
tions.67 Then, the rate of release of endogenous norepinephrine into plasma and the rate of 
clearance from the plasma can be estimated using equations.68 Unfortunately, laboratory 
measurements of norepinephrine in urine or plasma are expensive.
Because the measurement of muscle sympathetic nerve activity and catecholamines 
is invasive or expensive, these measurements are not easily employed in large epide-
miological studies. In the population studies described in this thesis, we rather used the 
following measures of ANS function: resting heart rate, heart rate variability, baroreflex 
sensitivity, Ewing tests and electrocardiographic measures of sympathetic activation. 
Resting heart rate is a measure of the sympathovagal balance.69 According to the 
Rosenblueth-Simeone model, heart rate is determined by the intrinsic heart rate multi-
plied by a sympathetic factor and a vagal factor.70 Impaired ANS function with increased 
sympathetic nervous system activation is reflected in a higher resting heart rate. In 
1981, the first findings on spectral analyses of heart rate fluctuations were published.71 
Heart rate variability is defined as the oscillations in the interval between consecutive 
heart beats.72 Heart rate variability is a manifestation of activity of the baroreflex, which 
purpose is to buffer blood pressure by adaptions in sympathetic and parasympathetic 
outflow.71, 73 Variability in heart rate can be expressed in several ways. In time domain 
analyses, a variety of statistical variables are calculated from intervals between adjacent 
normal R waves (NN intervals). The most commonly used time domain variables are the 
standard deviation of all NN intervals and the root mean square of successive differences 
between adjacent RR intervals.74 The frequency domain analyses quantify cyclic fluctua-
tions of NN intervals by the frequency of the fluctuation using Fourier transformation 
or autoregressive spectral analysis.72 High frequency fluctuations, with a frequency 
range of 0.15-0.40 Hz, are caused by respiration (if breathing is at high frequency75) and 
are effectuated by parasympathetic outflow. Low frequency fluctuations, in the range 
between 0.04 and 0.15 Hz, are the result of a blood pressure resonance phenomenon 
mediated by the baroreflexes and are effectuated by both sympathetic and parasympa-
thetic fluctuations in outflow.73, 76 Impaired function of the ANS is reflected in lower heart 
rate variability. Heart rate and heart rate variability can be determined from electrocar-
19
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1diographic recordings. The total variance in heart rate increases with the duration of the recording, because long measurements (e.g. 24 hours) include more rhythms (e.g. circa-
dian rhythm) than short measurements.72 In this thesis we used heart rate and heart rate 
variability from recordings ranging from 10 seconds to 24 hours. In addition to standard 
electrocardiographic recordings we also used the Actiheart device, an accelerometer 
combined with a heart rate monitor (CamNtech Ltd, Cambridge, United Kingdom) to 
calculate heart rate variability. The Actiheart device uses two electrodes at the level 
of the second intercostal space to measure the electrocardiogram (ECG), after which 
detection of heart beats occurs and interbeat intervals are recorded. The ECG itself is not 
stored. After extensive data processing, this recording can be used to estimate heart rate 
variability over a 24 hour period. The correlation between a Holter ECG and the Actiheart 
for estimating heart rate (variability) is high (correlation coefficient for mean RR interval 
0.998, 95% CI: 0.994-1.000).77
The changes in beat-to-beat heart rate are mediated by the baroreflexes. Therefore, also 
the quantification of baroreflex sensitivity is valuable in the assessment of ANS function.78 
Baroreflex sensitivity is estimated as the change in RR intervals divided by systolic blood 
pressure (ms/mmHg). Better ANS function is reflected in a higher baroreflex sensitivity.
Ewing tests have been important for many years in the detection of diabetic autonomic 
neuropathy.79 In chapter 3, we used four measures from the Ewing test battery. Three 
measures are obtained during an active change in position from lying to standing: the 
difference between the mean RR interval during one minute of rest prior to standing up 
and the minimum RR interval within 15 seconds after standing up (RRmax), the maxi-
mum RR interval between 15 and 30 seconds after standing up divided by the minimum 
RR interval 15 seconds after standing up (RRmax/min), and the systolic blood pressure 
difference (SBP difference) after standing up defined as the mean SBP over 30 seconds 
during 90-120 seconds after standing up, minus the mean over 30 seconds prior to 
standing up. Impaired ANS function is reflected in lower RRmax and RRmax/min and 
a larger (more negative) SBP difference. We also assessed the difference in maximum 
and minimum RR interval during inspiration and expiration averaged over six breaths 
(EI-difference) during deep breathing. Lower EI-difference is a reflection of impaired 
autonomic nervous system function.
Finally, three recent experimental studies showed that activation of the sympathetic 
nervous system is also reflected in changes on the standard ECG.80-82 These changes 
include alterations in conduction times and ventricular repolarization. In chapter 2 of 





The aim of this thesis was to investigate the role of the ANS in the development of 
diabetes and cardiovascular disease by using observational population studies. To this 
end, we used observational data from large cohort studies for causal inference, the 
process of drawing a conclusion about a causal connection. Causal inferences are most 
straightforward from randomized controlled trials. However, for the study of ANS func-
tion, randomized controlled trials are neither possible nor ethical. Observational studies 
may be used for causal inferences, after sources of bias have been taken into account, 
such as confounding and reverse causation.83
Confounding may occur in observational studies when the exposure and the outcome 
variable share a common cause that may obscure the causal association and explain the 
observed crude association.84 By adjusting for, or stratifying on, a confounding variable, 
the effect of the common cause may be eliminated from the association under study. In 
this thesis, we aimed to adjust our analyses for all known and measured confounding 
variables of the associations under study.
Reverse causation may occur especially in cross-sectional studies. When the exposure 
and outcome variables are measured at the same time, the observed exposure may be 
a consequence of the outcome variable rather than a cause. For example, when glucose 
tolerance and ANS function are associated in a cross-sectional study, it remains unclear 
whether glucose tolerances influences ANS function or vice versa. Longitudinal studies 
are less likely to suffer from reverse causation, as these studies provide information on 
the temporal relation between the exposure and outcome. However, in longitudinal 
studies reverse causation may also play a role when the outcome or disease of interest is 
already (subclinically) prevalent at baseline. For example, when ANS function is studied 
as a risk factor for the occurrence of cardiovascular disease after a myocardial infarction, 
we do not know whether impaired ANS function is merely a result of the myocardial 
infarction, or also a risk factor for cardiovascular disease in general.
In this thesis we used several approaches to overcome an effect of pre-existing diabetes 
and cardiovascular disease on ANS function in our studies. First, we excluded or adjusted 
for individuals with prevalent disease in our studies. Second, we restricted our analyses 
to populations without subclinical cardiovascular disease or diabetes at baseline; and 
third, we studied associations of ANS function with incident diabetes and cardiovascular 
disease using prospective follow-up studies. By studying first events of diabetes and 
cardiovascular disease during follow-up of individuals without pre-existing disease at 
baseline, we aimed to minimize a potential influence of underlying disease.
21
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Obesity is associated with sympathetic activation, but the role of different fat depots 
is unclear. The association between body fat, specifically visceral fat, and electro-
cardiographic measures of sympathetic activation in a population with structurally 
normal hearts was investigated.
Design and Methods
In this cross-sectional baseline analysis of the Netherlands Epidemiology of Obesity 
study, body fat percentage was assessed with BIA and abdominal subcutaneous (SAT) 
and visceral adipose tissue (VAT) with magnetic resonance (MR) imaging. Mean heart 
rate (HR) and five other electrocardiographic measures of sympathetic activation 
were calculated. We performed multivariate linear regression analyses.
Results
In 868 participants with a mean age (SD) of 55 (6) years, BMI of 26 (4) kg/m², 47% men, 
body fat was associated with HR and two other measures of sympathetic activation. 
Per sex-specific SD of total body fat, the difference in HR was 1.9 beats/min (95% 
CI: 1.0, 2.9; p<0.001) and per SD waist circumference 2.1 beats/min (95% CI: 1.3, 2.9; 
p<0.001). The difference in heart rate per SD VAT was 2.1 beats/min (95% CI: 1.3, 3.0; 
p<0.001).
Conclusions
Body fat, especially visceral fat, was associated with electrocardiographic measures 
of sympathetic activation. Our study implies that already before the onset of cardio-
vascular disease, excess (visceral) body fat is associated with sympathetic activation.
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INTRODUCTION
Obesity is associated with altered function of the autonomic nervous system.1-6 The 
autonomic nervous system controls homeostasis and regulates visceral functions by 
modulations in sympathetic and parasympathetic outflow. Altered autonomic function 
is characterized by reduced adaptive modulation and sympathetic activation. Neurohu-
moral activation increases the risk of both first and secondary cardiovascular events and 
is also associated with subclinical cardiovascular disease (CVD).7-9
Body fat may stimulate the sympathetic nervous system and induce autonomic 
dysfunction by the secretion of adipokines such as leptin, C-reactive protein, TNF-α, 
plasminogen activator inhitor-1 and interleukin-6. These cytokines either cross the 
blood-brain-barrier and directly stimulate the central sympathetic nervous system in 
the hypothalamus, or induce a state of low-grade inflammation that can also stimulate 
the sympathetic nervous system.10
In general, visceral fat seems stronger associated with CVD risk factors than subcutane-
ous fat. This may be explained by more macrophage infiltration and a higher secretion 
rate of pro-inflammatory cytokines.11-14 However, subcutaneous fat is the largest fat 
depot in the body, accounting for approximately 90% of total body fat. Therefore this 
depot may still be important in absolute contribution to sympathetic activation. Most 
previous studies on the association of body fat with sympathetic activation did not 
distinguish between different abdominal fat depots.1-4 We hypothesize that visceral fat 
is stronger associated with sympathetic activation than subcutaneous fat.
Electrocardiographic markers that are commonly used to study sympathetic activation 
are heart rate and heart rate variability.15, 16 Three recent experimental studies showed 
that the sympathetic overdrive is also reflected in other changes on the standard 
electrocardiogram (ECG).17-19 These changes include alterations in conduction times 
and ventricular repolarization. The ECG is an inexpensive, non-invasive and widely avail-
able diagnostic tool and may therefore be easy to use in large studies on sympathetic 
activation.
The aim of our study was to investigate to what extent overall and abdominal fat are 
associated with both established and novel measures of sympathetic activation in a 




Study design and population
The Netherlands Epidemiology of Obesity (NEO) study is a population-based prospective 
cohort study with oversampling of individuals with a BMI ≥ 27 kg/m². The design and data 
collection of the NEO study were described previously.20 The baseline visit was performed 
in the NEO study centre in the Leiden University Medical Centre. Prior to this study visit, 
participants fasted overnight and completed questionnaires. At the NEO study centre an 
extensive physical examination was performed. In a random subgroup of participants, 
magnetic resonance (MR) imaging scans of the abdomen and heart were performed.
The present study is a cross-sectional analysis of the baseline measurements of all partici-
pants with MR imaging of the heart and abdomen. Exclusion criteria for our study were 
self-reported CVD (defined as myocardial infarction, angina, congestive heart failure, 
stroke, or peripheral vascular disease), ejection fraction (EF) <50%, left ventricular hy-
pertrophy (LVH) (defined as >2SD deviation from the mean body surface area corrected 
left ventricular end-diastolic mass), prevalent diabetes mellitus (DM) (defined as use 
of glucose lowering drugs, fasting glucose concentration ≥7.0 mmol/L or postprandial 
glucose concentration ≥11.1 mmol/L), abnormal ECG or missing data on measures of 
body fat or sympathetic activation. For the analyses including heart rate or heart rate 
variability, we additionally excluded participants using beta blockers or calcium antago-
nists. For the analyses including QTc, Tpeak-end, spatial ventricular gradient or spatial 
QRS-T angle we additionally excluded participants with ventricular conduction defects. 
The NEO study was approved by the Medical Ethical Committee of the Leiden University 
Medical Centre. Before inclusion, all participants gave their informed consent.
Data collection
Self-identified ethnicity of participants was grouped into white (reference category) and 
other. Level of education was grouped in low education (defined as no education, pri-
mary education or lower vocational training) versus high education (reference). Tobacco 
smoking was categorized into current, former or never (reference) smokers. Physical ac-
tivity was expressed in MET-hours per week. Blood was sampled after an overnight fast of 
at least 10 hours. Two postprandial blood samples were taken 30 minutes and 2.5 hours 
after a liquid mixed meal (400 ml, 600 kcal). Fasting and postprandial glucose concentra-
tions were measured with the enzymatic colorimetric method (Roche Modular Analytics 
P800, Roche Diagnostics, Mannheim, Germany). Participants were asked to bring all 
their medication. The heart was imaged by MRI (1.5 Tesla MRI, Philips Medical Systems, 
Best, Netherlands) in short-axis view using an ECG-triggered balanced turbo-field-echo 
sequence. A 3-dimensional 3-directional velocity-encoded MRI technique was used. End 
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systolic and end diastolic ventricular masses and volumes were measured. Left and right 
stroke volumes (SV) were defined as the difference between the end diastolic volume 
and the end systolic volume. Left ventricular ejection fraction was calculated by dividing 
left ventricular SV by the end diastolic volume. The left ventricular mass was measured 
end diastolic and was standardized for body surface area.21
Body fat
Height and weight were measured without shoes and one kilogram was subtracted to 
correct for the weight of clothing. Body Mass Index (BMI) was calculated by dividing 
the weight in kilograms by the height in meters squared. The circumference of the 
waist (WC) was measured in the middle of the distance between the lowest rib and 
the crista iliaca superior with a flexible steal tape. Body fat percentage was measured 
using a bio-impedance device (TBF-310, Tanita International Division, UK). Abdominal 
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were quantified by 
MRI (1.5 Tesla MRI, Philips Medical Systems, Best, Netherlands) using a turbo spin echo 
imaging protocol. At the level of the fifth lumbar vertebra three transverse images with 
a slice thickness of 10 mm were obtained during a breath-hold. The fat depots were 
converted from the number of pixels to centimetres squared. The average of the three 
slices was used in the analyses.
Established and novel measures of sympathetic activation
A 12-lead ECG was obtained using a Mortara Eli-350 electrocardiograph (Mortara Instru-
ment Inc., Best, Netherlands) after a resting period of at least ten minutes. Standard 
10-second ECGs were stored in an 8-lead (I, II, II, V1-V6), 5000 sample comma-separated-
value file. The Kors matrix was used to calculate vector cardiograms (VCG) from the eight 
independent ECG leads.22 ECGs and VCGs were analyzed using the automatic MATLAB-
based (The MathWorks, Natick, MA) program BEATS and the semi-automatic program 
LEADS.23, 24
BEATS was used to detect the timings of all QRS complexes and calculated R-R intervals 
(ms). All ECGs were checked for falsely identified QRS complexes or non-sinus beats, 
and the timings were manually adjusted. Also the complexes surrounding the non-sinus 
beat were removed from the mean R-R interval calculations. Mean heart rate (HR) in 
beats/min was calculated as 60 divided by the mean R-R interval in seconds. The coef-
ficient of variation (CV) was expressed in percentage and calculated as the mean R-R 
interval divided by the standard deviation of the mean R-R interval x 100.
LEADS was used to calculate QT time (ms), QTc (corrected according to the Bazett for-
mula) and Tpeak-end duration (ms). The QRS and T integral vectors were approximated 
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by calculating the numerical sum of X-Y-Z deflections (amplitudes of positive deflections 
are added and those of negative deflections subtracted). The spatial QRS-T angle was 
defined as the angle (°) between the integral QRS vector and the integral T vector. The 
spatial ventricular gradient (mV*ms) was calculated as the vectorial sum of these vectors.
Statistical analyses
In the NEO study, individuals with a BMI ≥ 27 kg/m² were oversampled. To correctly 
represent associations in the general population, adjustments for the oversampling of 
individuals with a BMI ≥ 27 kg/m² were made.25 This was done by weighting individuals 
towards the BMI distribution of participants from the Leiderdorp municipality, whose 
BMI distribution was similar to the BMI distribution of the general Dutch population. All 
results were based on weighted analyses.
Baseline characteristics of the study population were stratified by categories of BMI.26 
Data were expressed as mean (SD), median (25th-75th percentile) or as percentage. The CV 
was ln-transformed. We performed linear regression analyses to examine the association 
between body fat and measures of sympathetic activation. As determinants we used 
BMI (kg/m²), total body fat (%), WC (cm), VAT (cm²) and SAT (cm²). We standardized these 
values to be able to compare the strength of the association between determinants. 
Standardization was performed separately for men and women because of the large dif-
ference in distribution. In addition, we tested for interaction between measures of body 
fat and sex by adding an interaction term to all linear regression models. As outcome 
variables we used HR (beats/min), CV (%), QTc time (ms), Tpeak-end duration (ms), the 
spatial ventricular gradient (mV*ms) and the spatial QRST angle (°). We calculated the 
difference and 95% confidence interval per SD of the determinant. For ln-transformed 
outcome variables, we expressed the regression coefficient as percentage difference. 
The crude associations were adjusted for age, sex, tobacco smoking, ethnicity, educa-
tion, physical activity and fasting state (yes/no). The analyses with VAT were additionally 
adjusted for SAT and vice versa.
RESULTS
Descriptive statistics
In total 6673 participants were included in the NEO study, 1205 with a MRI scan of 
abdomen and heart. We consecutively excluded participants with pre-existent CVD 
(n=104), prevalent diabetes (n=106), EF <50% (n=23), LVH (n=81), abnormal ECG (n=2) 
and missing data (n=21). The total population of the current study consisted of 868 
participants. For analyses on heart rate and the coefficient of variation we additionally 
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excluded participants using beta blockers or calcium antagonists (n=98), resulting in 
770 included participants. For the analyses including QTc, Tpeak-end, spatial ventricular 
gradient and spatial QRS-T angle we additionally excluded participants with ventricular 
conduction defects (n=73), resulting in 795 included participants. Because of the skewed 
distribution, the CV was ln-transformed.
Table 1: Baseline characteristics stratified by WHO categories of BMI (26)
BMI category (kg/m²)
< 25 (43%) 25-30 (45%) > 30 (12%)
Sex (% men) 35 54 42
Age (years) 56 (6) 55 (6) 55 (6)
Ethnicity (% Caucasian) 98 96 95
Smoking
Current (%) 9 14 13
Former (%) 40 44 52
Education (% low) 15 22 31
Total body fat (%)
Men 19 (3) 26 (3) 33 (4)
Women 32 (4) 39 (4) 46 (3)
Waist circumference (cm)
Men 88 (5) 99 (6) 113 (6)
Women 78 (7) 91 (7) 105 (8)
Mean VAT (cm²)
Men 73 (32) 120 (48) 176 (62)
Women 47 (26) 78 (31) 125 (49)
Mean SAT (cm²)
Men 150 (42) 209 (49) 327 (80)
Women 194 (54) 295 (54) 431 (94)
Heart rate (beats/min) 64 (10) 65 (10) 68 (10)
CV (%) 2.8 (1.7-4.5) 2.5 (1.6-4.0) 2.6 (1.6-4.1)
QTc (ms) 408 (27) 406 (26) 416 (26)
Tpeak-end (ms) 79 (14) 81 (13) 82 (15)
Ventricular gradient (mV*ms) 66 (24) 67 (25) 58 (20)
QRS-T spatial angle (°) 51 (26) 48 (25) 56 (30)
Data are presented as mean (SD), median (25th-75th percentile) or percentage. Results were based on 
weighted analyses (n=868)
BMI=body mass index; low education=no education, primary education or lower vocational training;




Baseline characteristics stratified by BMI categories (< 25 kg/m², 25-30 kg/m² (over-
weight), ≥ 30 kg/m² (obese)) are shown in Table 1. Participants with overweight were 
more often men. Obese individuals were on average less educated. Total body fat, waist 
circumference, visceral fat and subcutaneous fat were higher in de overweight and 
obese group than in the group with BMI < 25 kg/m².
Body fat, heart rate and coefficient of variation
The analyses on heart rate and the coefficient of variation included 770 participants. When 
stratified by BMI, heart rate was higher and the coefficient of variation in percentage was 
lower in the overweight and obese group than in the group with BMI < 25 kg/m² (Table 
1). The interaction terms between body fat measures and sex were non-significant in all 
linear regression models (p-values ranging from 0.41 to 0.84). This suggests that although 
women have a higher amount of total body fat than men, the association between body 
fat and sympathetic activation is not essentially different between men and women. BMI, 
Table 2: Difference (95% CI) in heart rate and coefficient of variation per SD of body fat
Fat measure (SD) Model Mean HR (beats/min) R² P-value CV (%) R² P-value
BMI (m: 3 kg/m²;
w: 4 kg/m²)
1 1.3 (0.4, 2.1) 0.01 0.004 −4 (−11, 2) 0.00 0.225
2 1.4 (0.5, 2.2) 0.05 0.001 −5 (−12, 2) 0.04 0.162
3 1.4 (0.6, 2.3) 0.07 0.001 −3 (−9, 3) 0.06 0.377
Total body fat
(m: 5%; w: 6%)
1 1.9 (1.0, 2.9) 0.04 <0.001 −5 (−12, 2) 0.00 0.204
2 1.9 (1.0, 2.8) 0.06 <0.001 −4 (−12, 3) 0.04 0.238
3 1.9 (1.0, 2.9) 0.09 <0.001 −2 (−9, 4) 0.06 0.446
WC (m: 9 cm;
w: 12 cm)
1 2.0 (1.1, 2.8) 0.04 <0.001 −6 (−13, 1) 0.01 0.095
2 2.0 (1.1, 2.8) 0.06 <0.001 −6 (−13, 1) 0.04 0.087
3 2.1 (1.3, 2.9) 0.09 <0.001 −4 (−11, 2) 0.06 0.149
VAT (m: 54 cm²;
w: 39 cm²)
1 2.3 (1.4, 3.2) 0.05 <0.001 −8 (−16, −1) 0.01 0.034
2 2.1 (1.3, 3.0) 0.07 <0.001 −7 (−15, 1) 0.04 0.081
3 2.1 (1.3, 3.0) 0.09 <0.001 −4 (−12, 3) 0.06 0.216
4 1.7 (0.6, 2.9) 0.10 0.004 −2 (−12, 7) 0.06 0.642
SAT (m: 71 cm²;
w: 98 cm²)
1 1.4 (0.5, 2.3) 0.02 0.002 −6 (−13, 1) 0.01 0.095
2 1.6 (0.8, 2.4) 0.05 <0.001 −7 (−14, 0) 0.04 0.048
3 1.7 (0.8, 2.5) 0.08 <0.001 −5 (−11, 0) 0.06 0.060
4 0.8 (−0.3, 1.9) 0.10 0.158 −4 (−12, 3) 0.06 0.248
Results were based on weighted analyses (n=770)
Model 1: Crude; 2: Adjusted for age and sex; 3: Adjusted for age, sex, smoking, ethnicity, education, physical 
activity and fasting state; 4: Model 3 + SAT (in VAT analyses) or Model 3 + VAT (in SAT analyses)
BMI=body mass index; WC=waist circumference; VAT=visceral adipose tissue; SAT=subcutaneous adipose 
tissue; HR=heart rate; CV=coefficient of variation
35
Body fat and sympathetic activation
2
total body fat percentage and waist circumference were positively associated with mean 
heart rate (Table 2). After adjustment for potential confounders, the association was the 
strongest for waist circumference. Per SD waist circumference (men: 9 cm; women: 12 
cm), the difference in heart rate was 2.1 beats/min (95% CI: 1.3, 2.9; p<0.001). There were 
no associations between body fat and the CV in the adjusted analyses.
As is shown in Table 2, VAT and SAT were both associated with heart rate after adjust-
ments for confounders. After adjustment for SAT, VAT remained independently associ-
ated with heart rate: per SD VAT the change in heart rate was 1.7 beats/min (95% CI: 0.6, 
2.9; p=0.004). However, the association between SAT and heart rate attenuated after 
adjustment for VAT to a difference of 0.8 beats/min (95% CI: −0.3, 1.9; p=0.158).
Body fat, QTc time and Tpeak-end
The analyses on QTc time and Tpeak-end included 795 participants. There was no 
significant interaction between body fat measures and sex in the linear regression 
analyses. Waist circumference was stronger associated with QTc than BMI or total body 
fat percentage. Per SD (men: 9 cm; women: 12 cm) increase in waist circumference, QTc 
increased with 4.5 ms (95% CI: 2.4, 6.6; p<0.001). No associations were observed with 
Tpeak-end (Table 3).
VAT was independently associated with QTc. After adjustment for all confounders and 
SAT, the change in QTc per SD VAT was 4.3 ms (95% CI: 1.8, 6.8; p=0.001). After adjusting 
for confounders and VAT, the difference in QTc per SD SAT was 1.0 ms (95% CI: −1.5, 3.4; 
p=0.448).
Body fat, spatial ventricular gradient magnitude and spatial QRS-T angle
Table 3 shows the results of the linear regression analyses between body fat and the 
spatial ventricular gradient and spatial QRS-T angle. There was no significant interaction 
between body fat measures and sex. BMI, total body fat and waist circumference were 
inversely associated with the ventricular gradient magnitude. Waist circumference was 
most strongly associated with the ventricular gradient magnitude with a difference of 
−3.4 mV*ms (95% CI: −5.6, −1.2; p=0.003) per SD waist circumference (9cm/12cm). After 
adjustment for potential confounders, BMI, total body fat and waist circumference were 
not associated with the spatial QRS-T angle.
After adjusting for confounders and SAT, the difference in the ventricular gradient per 
SD VAT was −4.4 mV*ms (95% CI: −7.0, −1.7; p=0.001). SAT was not associated with the 
ventricular gradient magnitude after adjustment for VAT. After adjustment for confound-
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Per SD SAT the change in QRS-T angle was −3.5° (95% CI: −6.2, −0.9; p=0.009) after all 
adjustments (Table 3).
DISCUSSION
In the present study, we observed that body fat (BMI, total body fat percentage) and 
abdominal body fat (waist circumference, VAT, SAT) were associated with mean HR, QTc 
and the ventricular gradient magnitude. No associations were observed of body fat with 
the CV and Tpeak-end duration. VAT was positively associated with the spatial QRS-T 
angle, independent of SAT. There was an inverse association between SAT and the spa-
tial QRS-T angle after adjustment for VAT. The associations between waist circumference 
and sympathetic activation were stronger than the associations between total body fat 
and sympathetic activation, suggesting that abdominal fat may be more important for 
autonomic function than overall fat. All associations were strongest for VAT and associa-
tions between SAT and sympathetic activation attenuated after adjustment for VAT. This 
indicates that different fat depots within the abdomen do not only differ in localization 
but also in function and that the visceral fat depot is most important with regard to 
sympathetic activation.
One strength of our study is that we excluded participants not only with pre-existent 
CVD but also with cardiac abnormalities diagnosed by MR imaging. Abnormalities in car-
diovascular structure and function are strongly associated with autonomic function.7-9 
The exclusion of participants with abnormal hearts reduced the possibility of reverse 
causation because of undetected CVD in our results. Another strength of our study is the 
availability of visceral and subcutaneous fat measured by MRI, in addition to BMI, waist 
circumference and total body fat percentage. This enabled us to study the association of 
the different abdominal fat depots with sympathetic activation.
A limitation of our study is the absence of a direct measure of sympathetic activation. In 
large epidemiological studies as ours, it is often not feasible to invasively or pharmaco-
logically measure sympathetic activity and we therefore used surrogate markers of sym-
pathetic activation. However, heart rate and heart rate variability are well-established 
parameters of autonomic function.15, 16 Heart rate is influenced by sympathetic and para-
sympathetic outflow to the sinus node, and dominant sympathetic activation over para-
sympathetic activation results in a higher heart rate and less variability in heart rate. In 
addition, we investigated four parameters of ventricular repolarization as novel markers 
of sympathetic activation. These parameters have not been validated as a markers of 
sympathetic activation. However, the influence of the sympathetic nervous system on 
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ventricular repolarization has long been recognized.27 In addition, three recent studies 
in which the sympathetic nervous system was experimentally stimulated (one in pigs 
and two in humans) have indicated that our study parameters are strongly influenced 
by the sympathetic nervous system.17-19 Because our study is an observational study, the 
indices of ventricular repolarization in our analyses may be influenced by factors other 
than sympathetic outflow, such as age, sex, physical activity and smoking. However, by 
adjusting for these factors, we aimed to minimize their influence on the associations 
between body fat and sympathetic activation. Another limitation is the use of a single 
ECG for the measurement of sympathetic activation, because previous studies have 
indicated that multiple ECGs give a more reliable estimate.28 However, any random mea-
surement error in the ECG measures would have diluted the true associations, leading to 
an underestimation in our results. A final limitation is the measurement of confounding 
variables by questionnaire (smoking, ethnicity, education and physical activity), which 
may have resulted in some misclassification. Because of this potential misclassification 
and the fact that this is an observational study, we cannot exclude the presence of 
residual confounding in our analyses.
The results of our study extend the knowledge from previous papers on body fat and 
sympathetic activation, by showing that abdominal fat, especially visceral fat, was 
stronger associated with sympathetic activation than fat mass in general. Previous 
studies observed an association between BMI and sympathetic activation.1, 2, 29 However, 
BMI may not be a valid measure to describe body composition because it does not 
distinguish between body fat and lean body mass. Total body fat percentage and waist 
circumference reflect body fat and to some extent fat distribution. In earlier papers, total 
body fat has been associated with different measurements of the autonomic nervous 
system, as has waist circumference.3-6, 30 In our study we measured BMI, total body fat 
percentage and waist circumference and because we used standardized values for these 
measures we were able to compare the strength of the associations with sympathetic 
activation.
Only a few studies were able to differentiate between visceral and subcutaneous fat 
depots. Three studies reported an association between VAT and sympathetic activa-
tion.31-33 Two of these papers also investigated SAT, and reported that VAT was stronger 
associated with sympathetic activation than SAT.32, 33 Another study reported that 
sympathetic activation in individuals with high subcutaneous fat was not different from 
non-obese individuals.34 We were able to extend these observations by showing that 
VAT was also associated with measures of sympathetic activation on the electrocardio-
gram (heart rate, QTc and the ventricular gradient) after adjustment for SAT, while the 
association of SAT with these measures attenuated after adjustment for VAT. Finally, in 
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line with our results, a recent paper observed an association of BMI with QTc, but not 
with Tpeak-end.35 We showed the same results for other body fat measures.
Our results suggest that subcutaneous fat is not associated with sympathetic activation, 
or that the association between SAT and sympathetic activation is mediated by VAT. 
Several mechanisms could underlie these associations. Adipocytes, or macrophages 
invading the adipose tissue, secrete a number of adipokines.10, 36 Distribution of the 
adipose tissue is a key determinant of this adipokine secretion. The secretion rate of pro-
inflammatory cytokines is higher in visceral fat than in subcutaneous fat. Furthermore, 
visceral fat inhibits the secretion of anti-inflammatory factors.11-14 Some pro-inflamma-
tory cytokines, such as leptin, can cross the blood-brain-barrier and directly stimulate 
the central sympathetic nervous system in the hypothalamus.10, 37 Other cytokines, for 
example C-reactive protein, TNF-α, plasminogen activator inhitor-1 and interleukin-6, 
cause a state of low-grade inflammation that can also stimulate the sympathetic nervous 
system.10, 13 Therefore, altered cytokine production may underlie the strong association 
between visceral fat and sympathetic activation. However, some studies have shown 
that leptin is more related to total or subcutaneous fat rather than to visceral fat.32, 34 If 
this is true, direct stimulation of the central nervous system by leptin could not explain 
our finding that visceral fat is strongest associated with sympathetic activation.
Because our study is cross-sectional, we cannot make any statements on the direction 
of the association. Therefore, a pathophysiological mechanism in which sympathetic 
activation promotes the accumulation of adipose tissue in the visceral compartment, 
could also explain our findings. Previous studies have shown that chronic activation 
of the sympathetic nervous system, caused by chronic stress or lack of physical activ-
ity could favour the accumulation of visceral fat.38, 39 This line of reasoning would also 
explain the inverse association we observed between SAT and the spatial QRS-T angle; 
less sympathetic activation, reflected in a smaller (more favourable) QRS-T angle, could 
stimulate the storage of fat in the subcutaneous instead of the visceral compartment.
The association between body fat and sympathetic activation may have clinical implica-
tions. A recent study in middle aged and elderly persons without manifest heart disease 
showed that each increment of 5 beats/min resulted in an 11% higher risk all-cause 
mortality (95% CI: 1-22; p=0.033) and a 12% higher rate of cardiovascular events (95% 
CI: 0-26; p=0.044) after 76 months of follow up.40 In our study, approximately 50 cm² 
of visceral adipose tissue was associated with an increase in resting heart rate of 2.1 
beats/min (95% CI: 1.3, 3.0; p<0.001). The explained variance was modest. However, 
because our population was free of CVD and diabetes, had structurally normal hearts 
and we adjusted for many factors that increase the risk of cardiovascular disease, our 
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results still suggest that body fat, especially visceral fat, may be important in the risk of 
cardiovascular events and mortality.
In conclusion, we observed that body fat, especially abdominal fat, is associated with 
sympathetic activation. Furthermore, visceral fat seems more important than sub-
cutaneous fat with regard to sympathetic activation. As participants in our study had 
structurally normal hearts, our results imply that already before the onset of CVD excess 
(abdominal) body fat is associated with sympathetic activation. Future prospective stud-
ies should investigate whether sympathetic activation is a mediator in the association 
between body fat and CVD.
41
Body fat and sympathetic activation
2
REFERENCE LIST
 1. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation in obese normotensive subjects. 
Hypertension 1995; 25: 560-563.
 2. Skrapari I, Tentolouris N, Perrea D, Bakoyiannis C, Papazafiropoulou A, Katsilambros N. Baroreflex 
sensitivity in obesity: relationship with cardiac autonomic nervous system activity. Obesity (Silver 
Spring) 2007; 15: 1685-1693.
 3. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve 
activity in healthy subjects. Circulation 1994; 89: 2634-2640.
 4. Peterson HR, Rothschild M, Weinberg CR, Fell RD, McLeish KR, Pfeifer MA. Body fat and the activity 
of the autonomic nervous system. N Engl J Med 1988; 318: 1077-1083.
 5. Poehlman ET, Gardner AW, Goran MI et al. Sympathetic nervous system activity, body fatness, and 
body fat distribution in younger and older males. J Appl Physiol 1995; 78: 802-806.
 6. Young JB, Troisi RJ, Weiss ST, Parker DR, Sparrow D, Landsberg L. Relationship of catecholamine 
excretion to body size, obesity, and nutrient intake in middle-aged and elderly men. Am J Clin 
Nutr 1992; 56: 827-834.
 7. Manfrini O, Pizzi C, Viecca M, Bugiardini R. Abnormalities of cardiac autonomic nervous activity 
correlate with expansive coronary artery remodeling. Atherosclerosis 2008; 197: 183-189.
 8. La Rovere MT, Bigger JT Jr., Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate 
variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic 
Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.
 9. Hillebrand S, Gast KB, de Mutsert R et al. Heart rate variability and first cardiovascular event in 
populations without known cardiovascular disease: meta-analysis and dose-response meta-
regression. Europace 2013; 15: 742-749.
 10. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol 
2012; 590: 1787-1801.
 11. Lemieux I, Pascot A, Prud’homme D et al. Elevated C-reactive protein: another component of the 
atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961-967.
 12. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects 
release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 
1998; 83: 847-850.
 13. He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B. Differences in plasminogen activa-
tor inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. 
Horm Metab Res 2003; 35: 178-182.
 14. Good M, Newell FM, Haupt LM, Whitehead JP, Hutley LJ, Prins JB. TNF and TNF receptor expression 
and insulin sensitivity in human omental and subcutaneous adipose tissue--influence of BMI and 
adipose distribution. Diab Vasc Dis Res 2006; 3: 26-33.
 15. Bootsma M, Swenne CA, Van Bolhuis HH, Chang PC, Cats VM, Bruschke AV. Heart rate and heart 
rate variability as indexes of sympathovagal balance. Am J Physiol 1994; 266: H1565-H1571.
 16. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. 
Task Force of the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. Eur Heart J 1996; 17: 354-381.
 17. Ramirez RJ, Ajijola OA, Zhou W et al. A new electrocardiographic marker for sympathetic nerve 




 18. Vahedi F, Haney MF, Jensen SM, Naslund U, Bergfeldt L. Effect of heart rate on ventricular 
repolarization in healthy individuals applying vectorcardiographic T vector and T vector loop 
analysis. Ann Noninvasive Electrocardiol 2011; 16: 287-294.
 19. Vahedi F, Odenstedt J, Hartford M, Gilljam T, Bergfeldt L. Vectorcardiography analysis of the 
repolarization response to pharmacologically induced autonomic nervous system modulation in 
healthy subjects. J Appl Physiol 2012; 113: 368-376.
 20. de Mutsert R, den Heijer M, Rabelink TJ et al. The Netherlands Epidemiology of Obesity (NEO) 
study: study design and data collection. Eur J Epidemiol 2013; 28: 513-523.
 21. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
 22. Kors JA, van HG, Sittig AC, van Bemmel JH. Reconstruction of the Frank vectorcardiogram from 
standard electrocardiographic leads: diagnostic comparison of different methods. Eur Heart J 
1990; 11: 1083-1092.
 23. Man SC, Van der Wall EE, Schalij MJ, Swenne CA. Beats: An interactive research oriented ECG 
analysis system. Computing in Cardiology 2010; 1007-1010.
 24. Draisma HH, Swenne CA, Van de Vooren H, Maan AC. LEADS: an interactive research oriented ECG/
VCG analysis system. Computing in Cardiology 2005; 32: 515-518.
 25. Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling de-
sign. Am J Public Health 1991; 81: 1166-1173.
 26. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity 
in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of 
Overweight in Adults. Am J Clin Nutr 1998; 68: 899-917.
 27. Abildskov JA. Neural mechanisms involved in the regulation of ventricular repolarization. Eur 
Heart J 1985; 6 Suppl D: 31-39.
 28. Schroeder EB, Whitsel EA, Evans GW, Prineas RJ, Chambless LE, Heiss G. Repeatability of heart rate 
variability measures. J Electrocardiol 2004; 37: 163-172.
 29. Antelmi I, de Paula RS, Shinzato AR, Peres CA, Mansur AJ, Grupi CJ. Influence of age, gender, body 
mass index, and functional capacity on heart rate variability in a cohort of subjects without heart 
disease. Am J Cardiol 2004; 93: 381-385.
 30. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal baroreflex gain in visceral obesity: 
implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 2002; 282: H630-H635.
 31. Poliakova N, Despres JP, Bergeron J, Almeras N, Tremblay A, Poirier P. Influence of obesity indi-
ces, metabolic parameters and age on cardiac autonomic function in abdominally obese men. 
Metabolism 2012; 61: 1270-1279.
 32. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. 
Circulation 2002; 106: 2533-2536.
 33. Gao YY, Lovejoy JC, Sparti A, Bray GA, Keys LK, Partington C. Autonomic activity assessed by heart 
rate spectral analysis varies with fat distribution in obese women. Obes Res 1996; 4: 55-63.
 34. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympa-
thetic neural activation. Am J Physiol Heart Circ Physiol 2004; 287: H414-H418.
 35. Braschi A, Abrignani MG, Francavilla VC, Francavilla G. Novel electrocardiographic parameters of 
altered repolarization in uncomplicated overweight and obesity. Obesity (Silver Spring) 2011; 19: 
875-881.
 36. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev 
Immunol 2011; 11: 85-97.
 37. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81(2): 223-241.
43
Body fat and sympathetic activation
2
 38. Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr Opin 
Pharmacol 2009; 9: 787-793.
 39. Mueller PJ. Physical (in)activity-dependent alterations at the rostral ventrolateral medulla: influ-
ence on sympathetic nervous system regulation. Am J Physiol Regul Integr Comp Physiol 2010; 
298: R1468-R1474.
 40. Johansen CD, Olsen RH, Pedersen LR et al. Resting, night-time, and 24 h heart rate as markers of 
cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. 



































































































































































































































































































































































































































































Autonomic function is not associated 
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Impaired autonomic function is a complication of type 2 diabetes mellitus (DM2), 
but may also be involved in its development. For this reason, this study looked at 
the association of autonomic function with the incidence of DM2 in a homogeneous 
Caucasian population.
Methods
The Hoorn study is a prospective population-based study of individuals aged 50–75 
years. For the 631 participants, the standard deviation of all normal-to-normal inter-
vals (SDNN) and eight other parameters of autonomic function were calculated at 
baseline. Fasting and 2-h glucose were measured during follow-up by oral glucose 
tolerance test (OGTT). DM2 at baseline and follow-up was ascertained by question-
naire and OGTT. After excluding participants with DM2 at baseline, the association 
of parameters of autonomic function with incident diabetes was examined using 
logistic-regression analysis while adjusting for possible confounders.
Results
After excluding those with known (n = 67) or newly diagnosed (n = 126) DM2 at base-
line and those missing follow-up data (n = 140), 298 participants were eligible for the 
study (182 with normal glucose tolerance, 19 with impaired fasting glucose and 97 
with impaired glucose tolerance). During a median follow-up of 9.2 (range 4.5–11.1) 
years, 94 incident cases of DM2 were observed. After adjusting for confounding vari-
ables, the DM2 odds ratio was 1.12 (95% CI: 0.77, 1.64) per SDNN increase. Results for 
other parameters of autonomic function were similar.
Conclusion
The present study found no evidence for an association of autonomic function with 
the incidence of DM2 in a population at high risk of diabetes. This implies that pre-
vously observed associations between autonomic function and glucose metabolism 
in cross-sectional settings may reflect reverse causation.
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INTRODUCTION
Type 2 diabetes mellitus (DM2) is an increasing public health problem1 and autonomic 
dysfunction is one of its complications.2 The autonomic nervous system is an involuntary 
nervous system with a sympathetic and a parasympathetic branch. Its purpose is to 
control homeostasis and regulate visceral functions. Autonomic dysfunction is charac-
terized by less adaptive changes and relative sympathetic overdrive and is associated 
with an increased risk of morbidity and mortality.3, 4 Previous cross-sectional studies 
showed that impaired autonomic function is associated with increased glucose levels 
and reduced glucose tolerance in various populations.5-9
Although altered autonomic function is considered a consequence of DM2, there are 
also indications that it may be involved in its development. First, autonomic function 
has been associated with glucose tolerance in normoglycemic individuals.10 Second, 
several organs involved in the glucose metabolism, such as the liver, pancreas, adrenal 
and skeletal muscles are autonomically innervated. The parasympathetic autonomic 
nervous system is responsible for the release of insulin from the pancreas and the insulin 
sensitivity of several organs. The decreased parasympathetic modulation in autonomic 
dysfunction may therefore play a role in the development of insulin resistance.11 Third, 
non-diabetic offspring of DM2 patients, who are at high risk of DM2, have a worse 
autonomic function than individuals of the same age without a family history of DM2, 
independent of other risk factors.12 These findings suggest that autonomic dysfunction 
may not only be a complication of DM2, but may also play a role in its development. 
Thus, the aim of the present study was to prospectively investigate the association 
between autonomic function and the incidence of DM2 in a middle-aged population.
METHODS
Study design and participants
The Hoorn study is a population-based cohort study of glucose tolerance and cardio-
vascular risk factors in a Caucasian population aged 50 to 75 years. Baseline data were 
collected from 1989 to 1991. Two follow-up visits were performed to record incident 
diagnoses of DM2: the first was between 1996 and 1998, and the second was between 
2000 and 2001. Details on the Hoorn study have been described elsewhere.13 In brief, a 
random sample of men and women aged 50 to 75 years was selected from the municipal 
registry of the town of Hoorn, the Netherlands. At baseline, 2484 persons participated 
in a study visit that included a 75-g oral glucose tolerance test (OGTT). Within 3 to 5 
weeks of the initial baseline visit, a subset of 631 individuals was invited for additional 
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baseline measurements. Selection of this subset was stratified by the 2-h glucose values 
of the first OGTT as well as age and gender. Because of the stratification by 2-h glucose 
values, the subset included 259 people with normal glucose tolerance (NGT), 28 with 
impaired fasting glucose (IFG), 151 with impaired glucose tolerance (IGT) and 193 with 
DM2. The additional baseline visit included measurements of autonomic function. The 
present study included all participants with available data for at least one parameter of 
autonomic function. Excluded were those with DM2 at baseline and with missing follow-
up data. The Hoorn study had the approval of the ethics committee of the VU University 
Medical Centre, and all study participants gave their informed consent.
Data collection
During the first baseline visit to the Hoorn study centre, extensive information on 
demographic characteristics, smoking behaviour, medical history and use of medica-
tion was obtained by questionnaire. Physical activity was measured by a sum score of 
nine equally weighted yes/no questions about the regular performance of the follow-
ing: sports, bicycling, gardening, walking, doing odd jobs, climbing stairs, household 
activities, daily food shopping and working.14 During the physical examination, weight 
and height were measured with the participants barefoot and wearing light clothing. 
Body mass index (BMI) was calculated as weight (kg) divided by the square of height 
(m²). Blood pressure was assessed twice on the right arm while sitting with a random-
zero sphygmomano-meter (Hawksley, Lancing, Sussex, UK), and the mean of the two 
measurements was used for the analyses. Hypertension was defined as systolic blood 
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
During both the first and additional baseline visit, blood samples were taken after over-
night fasting, and a 75-g OGTT administered to those with no previously diagnosed dia-
betes. Fasting and 2-h glucose concentrations were measured in plasma (mmol/L) using 
the glucose dehydrogenase method (Merck, Darmstadt, Germany). Baseline glucose 
concentrations were defined as the mean of the first and additional baseline measure-
ments. At baseline, participants were classified into categories of glucose tolerance 
according to World Health Organization (WHO) criteria.15 NGT was defined as fasting 
plasma glucose (FPG) < 6.1 mmol/L and 2-h plasma glucose (2-hPG) < 7.8 mmol/L. IFG 
was defined as FPG 6.1–6.9 mmol/Land 2-hPG < 7.8 mmol/L; IGT with or without IFG was 
defined as FPG < 7.0 mmol/L and 2-hPG 7.8–11.1 mmol/L; and DM2 was defined as FPG 
≥ 7.0 mmol/L or 2-hPG ≥ 11.1 mmol/L.
Fasting serum insulin levels were quantified by insulin-specific double-antibody radio-
immunoassay (antibody SP21, EMD Millipore, Billerica, MA, USA).
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Autonomic function tests
Participants were asked to refrain from smoking and drinking coffee for 2 hours prior to 
the additional baseline visit. Tests were performed at a temperature of 19–22°C between 
08.30 and 16.00 at least 1 hour after a light meal and with participants in supine position. 
The tests were preceded by a rest period of at least 10 minutes. During the tests, heart 
rate and blood pressure were continuously recorded on a PC-based data-acquisition 
system. RR intervals were obtained by a bipolar electrocardiography (ECG) chest lead 
and a QRS detector device with an accuracy of 1 ms. Blood pressure was recorded 
continuously using the Finapres (finger arterial blood pressure) method (model BP2000, 
GE Datex-Ohmeda, Madison, WI, USA), digitally sampled at 200 Hz, and offline low-pass-
filtered and down-sampled to 100 Hz. Systolic blood pressure values were obtained by 
an automated procedure verified by visual inspection.
Cardiac cycle duration (RR interval) and continuous finger arterial pressure were mea-
sured under three conditions: (1) spontaneous breathing for 3 min; (2) six deep breaths 
over 1 min; and (3) active change in position from supine to standing. The breathing 
frequency of six breaths/min was dictated by the investigator. When offline spectral 
analysis showed that the participants failed to breathe at the appropriate frequency, the 
recording was discarded. After each test, a rest period of 1 min was included to prevent 
any effects from previous tests.
During spontaneous breathing, the mean of the normal-to-normal RR intervals (NN 
intervals) and standard deviation of all NN intervals (SDNN) were calculated. Further-
more, spectral analysis was used to assess the power of the low-frequency (LF; 0.04–0.12 
Hz) and high-frequency (HF; 0.12–0.40 Hz) bands. Impaired autonomic function leads 
to lower values of these four measurements. From the deep-breathing recordings, it 
was possible to measure the difference in maximum and minimum RR intervals dur-
ing expiration and inspiration as averaged over six breaths (EI difference). Baroreflex 
sensitivity (BRS) was also calculated from the deep-breathing recordings, defined as 
the change in RR intervals caused by changes in systolic blood pressure (ms/mmHg) 
and estimated as the gain in transfer function between blood pressure and RR-interval 
changes. Only spectral components between 0.05 and 0.15 Hz were used, together 
with a squared coherence (χ²) of 0.5 or higher. Lower EI difference and BRS sensitivity 
are a sign of impaired autonomic function. During the active change in position from 
supine to standing, the difference between the mean RR interval during 1 min of rest 
prior to standing and the minimum RR interval within 15 s of standing (RRmax) was 
calculated. In addition, the maximum RR interval 15–30 s after standing divided by the 
minimum RR interval at around 15 s after standing (RRmax/min), and the systolic blood 
pressure difference (SBP difference) after standing, defined as the mean SBP over 30 s 
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within 90–120 s of standing minus the mean over 30 s prior to standing, were calcu-
lated. Impaired autonomic function is reflected by lower RRmax and RRmax/min, and 
a larger (more negative) SBP difference. In some cases, data were missing because the 
test schedule was not completed, the quality of data was inadequate for processing or 
non-sinus beats constituted > 10% of the total number of recorded beats.
In addition to individual parameters of autonomic function, a summary score of 
autonomic function was constructed, as described elsewhere.16 The results for each 
parameter of autonomic function were divided into quartiles. Each participant was as-
signed 0 points if the result was in the most abnormal quartile, 1 point if in the second 
quartile, 2 points if in the third quartile, and 3 points if in the best quartile of autonomic 
function. For all parameters except SBP difference, participants in the highest quartile 
had the best autonomic function. If all nine parameters were available, the scores for 
each were added together to construct a summary score. If one or two results were 
missing (41/298), these were replaced by the median value for that score. If three or 
more results were missing, the summary score was not calculated (59/298). Summary 
scores ranged from 0 (very poor) to 27 (very good).
Ascertainment of type 2 diabetes during follow-up
At the follow-up visits during 1996–1998 and 2000–2001, examinations including 
OGTTs were performed. New diagnoses of DM2 were ascertained during a follow-up 
visit using three methods: (1) by asking ‘Have you been diagnosed with DM2 since the 
last study visit?’ and ‘Which doctor monitors your DM2?’; (2) by recording the use of 
glucose-lowering medication; and (3) by OGTTs in participants with no known diabetes. 
DM2 was defined as FPG ≥ 7.0 mmol/L or 2-hPG ≥ 11.1 mmol/L. At the follow-up visits, 
both fasting and 2-h glucose concentrations were measured by the hexokinase method 
(Boehringer Ingelheim Pharma, Ingelheim, Germany) at follow-up.
Statistical analyses
Descriptive statistics were calculated as mean ± standard deviation (SD) or percentage 
for the total population and stratified by tertiles of SDNN. Also, differences in baseline 
characteristics between tertiles of autonomic function were tested by analysis of vari-
ance (ANOVA) for continuous variables and by chi-square test for categorical variables. 
As most cases of diabetes were detected at follow-up study visits and the exact dates 
of onset were unknown, it was not possible to use time-to-event analyses, so logistic 
regression was performed instead to study the association between the nine param-
eters of autonomic function at baseline and the incidence of DM2 at follow-up. The nine 
parameters were standardized to a mean of zero with 1 SD, and crude odds ratios (ORs) 
were calculated for these standardized parameters with 95% confidence intervals (CI), 
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while ORs were also adjusted for age (continuous), gender, BMI (continuous), hyperten-
sion (yes/no), prevalent cardiovascular disease (CVD; yes/no), cardiac medication (yes/
no), smoking (no smoking (reference), current smoking or former smoking), physical 
activity score (continuous), follow-up duration (continuous) and family history of DM 
(yes/no). In addition, baseline fasting glucose and insulin concentrations and 2-h glu-
cose concentrations (continuous) were added to the model to correct for the effects of 
glucose and insulin concentrations on autonomic function. These analyses were also 
performed in a subgroup of individuals with NGT at baseline. For these participants, a 
composite endpoint consisting of the development of IFG, IGT or DM2 was calculated, 
using data from the last available follow-up. The same logistic regression analyses were 
performed with this composite endpoint as outcome.
Also, linear regression analysis was performed to examine the association of autonomic 
function with continuous fasting and 2-h glucose concentrations at the follow-up visits, 
using glucose concentrations from the last available follow-up visit. Statistical analyses 




A total of 631 participants had measurements of autonomic function at baseline. Exclud-
ed were those with known (n = 67) or newly diagnosed (n = 126) DM2 at baseline. Of the 
438 remaining participants, 140 had missing follow-up data. Also, 51 participants died, 
30 moved to another region and, for 59 participants, the reason for not attending the 
follow-up visit was unknown. Those with missing follow-up data were somewhat older 
(SD) at 66 (7) years compared with 63 (7) years, had higher 2-h glucose levels at 7.1 (2) 
mmol/L compared with 6.6 (2.0) mmol/L and more often used cardiac medication, with 
27% using compared with 19% not. All parameters of autonomic function were slightly 
lower in those lost to follow-up: their mean (SD) NN interval was 929 (133) ms compared 
with 974 (152) ms, while BRS was 8 (4) ms/mmHg compared with 9 (6) ms/mmHg.
The present study ultimately included 298 participants: 182 with NGT; 19 with IFG; and 
97 with IGT. Their mean age (SD) was 63 (7) years, 51% were male and their mean (SD) 
BMI was 26 (3) kg/m². Baseline characteristics for the entire study population (n = 298) 
by tertiles of SDNN (n = 272) are shown in Table1.
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Those in the highest tertile of SDNN were younger, more often male, less often hyper-
tensive and less often used cardiac medication than those in the lowest SDNN tertile. 
The prevalence of CVD was highest in the lowest tertile of SDNN. All participants had at 
least one parameter of autonomic function available, the values of which are presented 
in Table 2. The first follow-up visit included 286 participants and, of these, 230 attended 
the second follow-up visit whereas nine participants only attended the second follow-up 
visit. For one participant the exact date of the follow-up visit was unknown. The median 
follow-up duration was 9.2 (range 4.5–11.1) years.
Autonomic function and incidence of DM2
Of the 298 participants included in the analyses, 94 developed DM2 at one of the follow-
up visits: 24 from the NGT group; 10 from the IFG group; and 60 from the IGT group. 
At the first follow-up visit (1996–1998), there were 67 cases of DM2 and, at the second 
follow-up visit (2000–2001), 27 cases of DM2. The ORs (95% CI) for DM2 associated with 
parameters of autonomic function are shown in Table 3. After adjusting for confounding 
factors and glucose and insulin levels, ORs ranged from 0.88 (0.59, 1.31) to 1.36 (0.93, 
1.98) and were all non-significant. In addition to individual parameters of autonomic 
Table 1: Baseline characteristics for the total study population (n=298) and stratified by tertiles of SDNN 
(n=272)
Total SDNN (ms) in tertiles
11-29 ms 30-42 ms 43-118 ms
N 298 91 91 90
Sex (% men)* 51 48 42 62
Age (years)* 63 (7) 64 (7) 63 (7) 61 (6)












Fasting glucose (mmol/L) 5.5 (0.6) 5.6 (0.6) 5.5 (0.5) 5.5 (0.5)
2-hour glucose (mmol/L) 6.7 (2.0) 7.0 (2.0) 6.5 (1.9) 6.5 (2.0)
Activity score (scale 0-9) 6 (2) 5 (2) 6 (1) 6 (2)
Hypertension (%)* 30 42 24 20
Prevalent CVD (%)* 13 18 8 9
Use of cardiac medication (%)* 19 30 13 11
Family history of DM (%) 26 24 25 27
IFG or IGT at baseline (%) 39 42 40 33
Data are presented as mean (SD) or percentage
*p-value<0.05
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function, a summary score of autonomic function was calculated. For every SD of the 
summary score, the adjusted OR for DM2 was 1.36 (0.92, 2.01).
Autonomic function and fasting and 2-h glucose concentrations at follow-up
The linear regression analyses used glucose concentrations from the last available 
follow-up visit (104 from the first follow-up visit and 194 from the second). The Figure 
shows the crude associations of SDNN (ms) at baseline with fasting (A) and 2-h (B) 
Table 2: Parameters of autonomic function
Parameter of autonomic function N Mean (SD)
Mean NN (ms) 272 974 (152)
SDNN (ms) 272 38 (17)
LF power (ms²) 272 264 (121-547)*
HF power (ms²) 272 206 (94-451)*
EI-difference (ms) 278 193 (108)
BRS (ms/mmHg) 260 9.4 (5.6)
RR max (ms) 279 260 (98)
RR max/min (ms) 279 1.3 (0.2)
SBP difference (mmHg) 256 −5.5 (14.8)
Summary score 234 14 (6)
*Median (25th-75th percentile)
Table 3: Odds ratio and 95% CI for the incidence of type 2 diabetes per SD of parameters of autonomic 
function
N Events SD Model 1 Model 2 Model 3 Model 4
Mean NN (ms) 272 85 152 0.87 (0.67, 1.13) 0.87 (0.67, 1.14) 0.86 (0.65, 1.14) 1.01 (0.69, 1.47)
SDNN (ms) 272 85 17 0.89 (0.68, 1.16) 0.93 (0.71, 1.22) 0.92 (0.69, 1.23) 1.12 (0.77, 1.64)
Ln LF power (ms²) 272 85 1 1.00 (0.78, 1.30) 1.08 (0.82, 1.41) 1.09 (0.81, 1.47) 1.21 (0.82, 1.77)
Ln HF power (ms²) 272 85 1 0.95 (0.74, 1.23) 0.99 (0.76, 1.29) 0.93 (0.71, 1.23) 1.17 (0.81, 1.68)
EI-difference (ms) 278 88 108 1.06 (0.82, 1.36) 1.13 (0.87, 1.47) 1.13 (0.85, 1.51) 1.36 (0.93, 1.98)
BRS (ms/mmHg) 260 82 5.6 0.98 (0.75, 1.28) 1.00 (0.76, 1.31) 1.03 (0.77, 1.36) 1.23 (0.83, 1.83)
RR max (ms) 279 90 98 0.79 (0.60, 1.04) 0.82 (0.62, 1.08) 0.82 (0.60, 1.09) 0.92 (0.62, 1.35)
RR max/min (ms) 279 90 0.2 1.03 (0.80, 1.32) 1.11 (0.84, 1.46) 1.17 (0.88, 1.57) 1.35 (0.94, 1.95)
SBP difference 
(mmHg)
256 82 14.8 0.91 (0.70, 1.18) 0.92 (0.70, 1.20) 0.90 (0.67, 1.20) 0.88 (0.59, 1.31)
Summary score 262 84 6 0.95 (0.73, 1.23) 0.99 (0.75, 1.31) 1.04 (0.78, 1.39) 1.36 (0.92, 2.01)
Model 1: crude
Model 2: adjusted for age and sex
Model 3: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration and family history of DM
Model 4: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration, family history of DM, and baseline glucose and insulin concentrations
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plasma glucose concentrations (mmol/L) at the time of the last available follow-up. The 
associations between parameters of autonomic function and glucose concentrations 
were small, and only the relationship between the EI difference and fasting glucose was 
statistically significant after adjustment (mean increase was 0.20 mmol/L (95% CI: 0.03, 
0.36) per SD increase in EI difference). All other associations were not significant after ad-
justing for age, gender, BMI, hypertension, prevalent CVD, cardiac medication, smoking, 
physical activity, follow-up duration, and baseline glucose and insulin concentrations. 
The summary score of the autonomic function tests also showed no relationship. For 
every SD of the summary score, the adjusted difference in fasting glucose concentration 
at follow-up was 0.09 (−0.09, 0.27) mmol/L, with a 2-h glucose concentration of 0.09 
(−0.25, 0.43) mmol/L (Table 4).
Autonomic function and incidence of DM2 in participants with normal glucose 
tolerance at baseline
In the subgroup of 182 participants with NGT at baseline, 24 developed DM2. Sixteen 
cases were detected at the first follow-up visit and eight at the second follow-up (Table 
5). ORs were close to 1 and comparable to those for the total study population. In ad-
dition, there was no association between the summary score of autonomic function 
and DM2 incidence in participants with NGT at baseline (adjusted OR: 1.13, 95% CI: 
0.60, 2.15). For participants with IFG or IGT at baseline, the OR for DM2 per SD of the 
summary score was 1.43 (0.72, 2.85), indicating that reverse causation may have been 
involved. Of the 182 participants who had NGT at baseline, 72 reached the composite 
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Figure. Scatter plots of the standard deviation of all normal-to-normal intervals (SDNN; ms) at baseline, and 
fasting (A) and 2-h (B) glucose concentrations (mmol/L) at the last available follow-up study visits.
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endpoint of IFG/IGT/DM2 (24 cases at the first follow-up and 48 at the second). All ORs 
were non-significant (Table 6). Linearregression analyses with parameters of autonomic 
Table 4: Associations between parameters of autonomic function with fasting and 2-hour glucose 
concentrations at follow-up
Difference in fasting glucose 
(mmol/L) (95% CI)¹
Difference in 2-hour glucose 
(mmol/L) (95% CI)¹
SD Crude Adjusted² Crude Adjusted²
Mean NN (ms) 153 −0.08 (−0.26, 0.10) 0.03 (−0.14, 0.20) −0.11 (−0.53, 0.28) 0.18 (−0.15, 0.50)
SDNN (ms) 17 −0.04 (−0.22, 0.14) 0.08 (−0.08, 0.25) −0.23 (−0.63, 0.16) 0.12 (−0.20, 0.45)
Ln LF power (ms²) 1 −0.01 (−0.19, 0.17) 0.08 (−0.10, 0.25) −0.24 (−0.64, 0.15) −0.06 (−0.39, 0.27)
Ln HF power (ms²) 1 0.10 (−0.08, 0.28) 0.14 (−0.02, 0.31) −0.14 (−0.54, 0.26) 0.18 (−0.14, 0.50)
EI-difference (ms) 108 0.19 (0.01, 0.36) 0.20 (0.03, 0.36) −0.29 (−0.68, 0.11) 0.00 (−0.33, 0.33)
BRS (ms/mmHg) 6 0.09 (−0.09, 0.28) 0.14 (−0.04, 0.31) −0.28 (−0.69, 0.14) 0.06 (−0.27, 0.40)
RR max (ms) 98 −0.19 (−0.37,−0.02) −0.04 (−0.20, 0.12) −0.32 (−0.71, 0.07) 0.00 (−0.32, 0.31)
RR max/min (ms) 0.2 −0.10 (−0.27, 0.08) 0.00 (−0.17, 0.17) −0.19 (−0.57, 0.21) 0.13 (−0.19, 0.46)
SBP difference (mmHg) 15 0.02 (−0.16, 0.21) 0.01 (−0.16, 0.18) −0.23 (−0.64, 0.20) −0.04 (−0.37, 0.29)
Summary score 6 −0.08 (−0.27, 0.10) 0.09 (−0.09, 0.27) −0.25 (−0.66, 0.16) 0.09 (−0.25, 0.43)
¹ Difference (95% CI) in glucose concentrations per SD increase of parameters of autonomic function
² Adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical activity, 
follow-up duration, family history of DM, and baseline glucose and insulin concentrations
Table 5: Odds ratios and 95% CI for the incidence of type 2 diabetes per SD of parameters of autonomic 
function in the individuals with normal glucose tolerance at baseline
N Events SD Model 1 Model 2 Model 3 Model 4
Mean NN (ms) 168 23 154 0.95 (0.61, 1.48) 0.95 (0.60, 1.48) 0.78 (0.46, 1.33) 0.79 (0.39, 1.58)
SDNN (ms) 168 23 18 1.01 (0.64, 1.57) 1.02 (0.65, 1.61) 0.98 (0.59, 1.61) 0.99 (0.55, 1.78)
Ln LF power (ms²) 168 23 1 1.16 (0.75, 1.80) 1.19 (0.75, 1.90) 1.26 (0.75, 2.11) 1.39 (0.75, 2.58)
Ln HF power (ms²) 168 23 1 0.91 (0.58, 1.42) 0.91 (0.58, 1.44) 0.84 (0.52, 1.36) 0.87 (0.48, 1.59)
EI-difference (ms) 173 24 108 0.95 (0.61, 1.48) 0.95 (0.59, 1.50) 1.01 (0.60, 1.70) 1.16 (0.65, 2.08)
BRS (ms/mmHg) 159 22 5 0.91 (0.56, 1.46) 0.87 (0.53, 1.42) 0.81 (0.46, 1.43) 0.89 (0.43, 1.84)
RR max (ms) 172 24 99 0.77 (0.46, 1.27) 0.76 (0.45, 1.27) 0.69 (0.39, 1.22) 0.74 (0.38, 1.45)
RR max/min (ms) 172 24 0.2 1.04 (0.69, 1.59) 1.05 (0.67, 1.65) 1.05 (0.64, 1.73) 1.08 (0.63, 1.84)
SBP difference 
(mmHg)
156 21 15 1.29 (0.82, 2.05) 1.29 (0.81, 2.06) 1.11 (0.62, 1.98) 0.89 (0.44, 1.79)
Summary score 162 23 6 0.99 (0.64, 1.55) 1.00 (0.63, 1.59) 1.03 (0.61, 1.73) 1.13 (0.60, 2.15)
Model 1: crude
Model 2: adjusted for age and sex
Model 3: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration and family history of DM
Model 4: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration, family history of DM, and baseline glucose and insulin concentrations
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function as determinants, and fasting and 2-h glucose at the last available follow-up visit 
as outcomes, also showed no significant associations (data not shown).
DISCUSSION
The present study aimed to examine the association between autonomic function and 
the incidence of DM2 in a homogeneous Caucasian population aged 50–75 years. Non-
significant associations were observed between nine parameters of autonomic function 
(mean NN interval, SDNN, LF power, HF power, EI difference, BRS, RRmax, RRmax/min and 
SBP difference) and DM2 after a median follow-up duration of 9.2 (range: 4.5–11.1) years. 
In addition, a summary score of all nine functions was not associated with incident DM2. 
The associations between parameters of autonomic function and fasting and 2-h glucose 
concentrations at the last available follow-up visit were small and non-significant, with 
the exception of an unexpected positive association between EI difference and fasting 
glucose during follow-up. To exclude the influence of higher glucose concentrations on 
autonomic function, two analyses were performed in individuals with NGT at baseline, 
one with DM2 and another with a composite endpoint including IFG, IGT and DM2 as 
outcomes. There were no significant associations between any of these parameters of 
autonomic function and DM2 incidence.
Table 6: Odds ratios and 95% CI for the incidence of IFG, IGT or DM2 per SD of parameters of autonomic 
function in individuals with normal glucose tolerance at baseline
N Events SD Model 1 Model 2 Model 3 Model 4
Mean NN (ms) 168 66 154 0.98 (0.72, 1.34) 0.98 (0.72, 1.34) 1.08 (0.77, 1.51) 1.16 (0.80, 1.69)
SDNN (ms) 168 66 18 0.92 (0.67, 1.27) 0.91 (0.66, 1.26) 0.90 (0.63, 1.28) 0.90 (0.62, 1.31)
Ln LF power (ms²) 168 66 1 0.79 (0.58, 1.09) 0.76 (0.54, 1.07) 0.75 (0.52, 1.07) 0.71 (0.48, 1.05)
Ln HF power (ms²) 168 66 1 1.01 (0.74, 1.38) 1.01 (0.73, 1.40) 0.98 (0.69, 1.38) 1.04 (0.72, 1.50)
EI-difference (ms) 173 71 108 0.91 (0.67, 1.24) 0.91 (0.66, 1.26) 0.80 (0.56, 1.15) 0.78 (0.53, 1.14)
BRS (ms/mmHg) 159 68 5 0.93 (0.68, 1.29) 0.96 (0.69, 1.33) 0.88 (0.61, 1.26) 0.94 (0.63, 1.38)
RR max (ms) 172 69 100 0.87 (0.63, 1.20) 0.86 (0.62, 1.20) 0.93 (0.67, 1.31) 1.01 (0.71, 1.44)
RR max/min (ms) 172 69 0.2 0.84 (0.61, 1.16) 0.83 (0.59, 1.17) 0.84 (0.57, 1.23) 0.86 (0.59, 1.27)
SBP difference 
(mmHg)
156 63 15 1.02 (0.74, 1.40) 1.01 (0.73, 1.39) 0.97 (0.66, 1.43) 0.92 (0.61, 1.39)
Summary score 162 63 6 0.75 (0.54, 1.03) 0.72 (0.51, 1.02) 0.72 (0.50, 1.04) 0.75 (0.50, 1.12)
Model 1: crude
Model 2: adjusted for age and sex
Model 3: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration and family history of DM
Model 4: adjusted for age, sex, BMI, hypertension, prevalent CVD, cardiac medication, smoking, physical 
activity, follow-up duration, family history of DM, and baseline glucose and insulin concentrations
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An important strength of the present study was its prospective design. Cross-sectional 
studies fail to provide information on causal relationships between autonomic function 
and glucose tolerance, particularly because glucose and insulin concentrations can also 
influence autonomic function.17-20 The present prospective study was able to investigate 
the temporal relationship between autonomic function and the development of DM2.
By adjusting the analyses for baseline glucose and insulin concentrations and perform-
ing the analyses in individuals with NGT at baseline, it was possible to correct for the 
possible effect of baseline glucose and insulin levels on autonomic function (reverse 
causation).
Another strength was the use of OGTTs for the diagnosis of DM2 at follow-up, as this test 
is more reliable than self-reporting for diagnosis of DM2 and also identifies diabetics who 
have not yet been diagnosed by their physicians.21 Furthermore, we used an extensive 
set of parameters of autonomic function that can be divided in three categories. Four 
parameters (EI-difference, RRmax, RRmax/min and SBP difference) are part of the Ewing 
test battery.22 These tests evaluate cardiovascular autonomic reflexes and are indicative 
of sympathetic (EI-difference and RRmax) or parasympathetic (EI-difference, RRmax, 
RRmax/min and SBP difference) integrity. The value of Ewing tests has been extensively 
evaluated and the tests are used in clinical practice for the assessment of (diabetic) 
neuropathy.23 The second category of autonomic function tests are the heart rate (vari-
ability) parameters: mean NN, SDNN, LF power and HF power. The mean NN interval is 
the reciprocal of mean heart rate and is indicative of the sympathovagal balance, with 
shorter NN intervals representing more sympathetic activation.24 Heart rate variability is 
the result of autonomic modulations of the sympathetic and parasympathetic nervous 
system, with the purpose to buffer blood pressure.25, 26 Finally, baroreflex sensitivity is 
defined as the reflex-induced change in interbeat interval in milliseconds per millimeter 
of Hg blood pressure change and describes the functioning of the baroreflexes in short 
term regulation of arterial blood pressure.27 The use of three categories of autonomic 
function parameters enabled us to evaluate several aspects of the autonomic nervous 
system and is therefore an important strength of our study.
On the other hand, one limitation of the present study was the small sample size of 
298 participants, which may have resulted in insufficient power. The proportion of 
IFG and IGT cases at baseline was high because of oversampling of such individuals in 
the study population, and this contributed to the 94 cases of DM2 found at follow-up. 
Yet, despite the small sample size, overall there were no indications of any association 
between autonomic function and incidence of DM2. The associations with fasting and 
2-h glucose concentrations were small, and the limits of the 95% CI excluded large ef-
fects. For this reason, it is not believed that associations would be detected with larger 
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sample sizes and power. The present limited sample size was in large part the result 
of non-participation in the follow-up visits (140 of the 438 non-diabetic participants at 
baseline did not participate, 51 died, 29 moved and, for 59 the reason for not attend-
ing was unknown). In fact, the 298 participants included in our analyses were healthier 
and had better autonomic function than the 140 who were lost to follow-up. The as-
sociation between autonomic function and DM2 among non-participants may have 
been stronger than among participants, and this may have led to underestimation of the 
true association between autonomic function and DM2 in our analyses. However, even 
with a hypothetical worst-case scenario in which all participants who did not return for 
follow-up developed DM2, analysis would still not have found a significant association 
between parameters of autonomic function and incidence of DM2 (data not shown).
Several cross-sectional studies have shown an association between autonomic function 
and glucose tolerance.5-9 Four previous studies prospectively investigated the associa-
tion between autonomic function and incident DM2. Shigetoh et al found a significant 
OR (5.39, 95% CI: 1.34, 21.8) for the development of DM2 in individuals with a heart rate 
≥80 beats/min as compared with a heart rate <60 beats/min (n=614, number of incident 
cases of DM2 not reported).28 However, it is unclear whether individuals with known DM2 
at baseline were excluded from this study and therefore the results may be biased. An 
analysis on the Chicago Heart Association Detection Project in Industry showed an as-
sociation for 1 SD increase in heart rate (12 beats/min) and diabetes mortality (n=14992, 
400 cases of diabetes mortality): OR=1.21, 95% CI: 1.03-1.41) in individuals aged 35-49 
years. Heart rate was also associated with non-fatal DM2, but this association attenuated 
after adjustment for BMI and post load glucose concentrations at baseline.29 Since we 
only investigated non-fatal DM2 and not diabetes mortality, these results are comparable 
to our study. The ARIC study (n=8185, 1063 incident cases of DM2) showed an associa-
tion of resting heart rate with DM2 after adjustment for confounding including baseline 
glucose (relative risk per SD (9.7 beats/min) = 1.06 (95% CI 1.00, 1.13). A comparable as-
sociation was observed in individuals with normal fasting glucose at baseline (RR=1.13, 
95% CI: 1.04, 1.22). In line with our study, there were no associations between LF and 
HF power and SDNN with DM2.30 The ARIC study is comparable with the Hoorn study 
in design. An important difference is the inclusion of more ethnic groups (mainly black, 
19%) in the ARIC study. The influence of ethnicity on autonomic function is unknown, 
but differences in glucose metabolism have been shown between ethnic groups.31 The 
CARDIA study (n=3295, 98 incident cases of DM2) showed an association between low 
heart rate recovery and incident DM2 in individuals with poor fitness (OR=3.27, 95% CI 
1.34, 7.94), but not in fit persons.32 In our study, there was no association in either fit 
or unfit participants after stratification for regular physical activity (defined as at least 
five days a week moderately active) (data not shown). However, the population of the 
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CARDIA study is much younger than the population of the Hoorn study (18-30 years 
versus 50-75 years). It is possible that physical activity is an important effect modifier 
in young individuals, but is less important in older age due to an entirely different risk 
profile. Slow heart rate recovery may reflect decreased parasympathetic activity.33 Our 
study did not investigate heart rate recovery, which is defined as the rapid decrease 
in heart rate following cessation of exercise, but a previous study showed a significant 
association between heart rate variability and heart rate recovery.34 Therefore it would 
be expected that the association of heart rate recovery and heart rate variability with 
DM2 would be comparable. However, the results of the CARDIA study are not adjusted 
for glucose concentrations at baseline. Since glucose concentrations at baseline are a 
strong predictor for the development of DM2, results may suffer from reverse causation.35 
Overall, the results from previous prospective studies are inconsistent. Furthermore, our 
study used more parameters of autonomic function than the previous studies. It has 
been shown that relying on one parameter may result in over- or underestimation of the 
autonomic function.22 This may explain the incidental significant results that were found 
earlier. In our study we examined several aspects of the autonomic nervous system and 
we consistently found no evidence for an association with DM2.
The results of cross-sectional studies have identified an association between autonomic 
function and glucose tolerance that may be bidirectional. Some studies suggested that 
autonomic dysfunction may not only be a complication of DM2, but may also be involved 
in its development. However, in our prospective analysis there was no association be-
tween autonomic function and DM2. This suggests that autonomic dysfunction is solely a 
consequence of glucose concentrations and is not involved in the development of DM2. 
Such a link was proposed in 1986 by Landsberg, who postulated that the sympathetic 
activation associated with obesity is mediated by insulin resistance and concomitant 
hyperinsulinaemia.36 Experimental studies in humans showed that hyperinsulinaemia 
caused by the infusion of insulin enhanced sympathetic activation and depressed vagal 
activation.17, 18 This decreased autonomic function may be the result of sympathetic activa-
tion caused by insulin acting in the hypothalamus.37 Also hyperglycaemia has been associ-
ated with sympathetic activation.19, 38 These studies indicate that hyperinsulinaemia and 
hyperglycaemia may be the underlying factor of the previously reported cross-sectional 
association between impaired glucose metabolism and sympathetic activation.
In conclusion, there is no evidence from the present study of any association between 
autonomic function and the incidence of DM2 and fasting glucose concentrations in 
the follow-up of a homogeneous Caucasian population aged 50–75 years. These results 
suggest that previously observed associations between autonomic function and glucose 
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Excess body fat is associated with altered autonomic function. We investigated 
whether this association is mediated by insulin resistance.
Methods and Results
Cross-sectional analysis of a subgroup of the Netherlands Epidemiology of Obesity 
study with measurements of autonomic function (heart rate variability calculated as 
mean interbeat interval, standard deviation of all normal intervals (SDNN), low fre-
quency (LF) power and high frequency (HF) power). We measured BMI (kg/m²), total 
body fat (%) and waist circumference (cm), and calculated the HOMA-index of insulin 
resistance (HOMA-IR). We examined the association between body fat and heart rate 
variability with multivariate linear regression analysis. To investigate whether the as-
sociation was mediated by insulin resistance, we additionally adjusted for HOMA-IR.
After exclusion of participants with glucose lowering medication (n=19), 466 par-
ticipants were included. Per SD of BMI, the difference in SDNN was −2.7% (95% CI: 
−5.5, 0.1) in the multivariate model. Additional adjustment for HOMA-IR attenuated 
this association to −1.2% (95% CI: −4.2, 1.7), suggesting that 55% of the association 
between BMI and SDNN was mediated by HOMA-IR. All measures of body fat were 
associated with mean interbeat interval, SDNN and LF power. Depending on the pa-
rameter of body fat or heart rate variability, 29-81% of the association was mediated 
by HOMA-IR.
Conclusion
In this cross-sectional study, body fat was associated with heart rate variability. This 
association may at least partially be mediated by insulin resistance. Future studies 
should investigate whether a reduction in obesity and insulin resistance may prevent 
the adverse cardiovascular consequences of altered autonomic function.
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INTRODUCTION
Excess body fat is associated with altered function of the autonomic nervous system and 
sympathetic activation.1,2 Altered autonomic function is an independent risk factor for 
cardiovascular events in populations with prevalent cardiovascular disease,3,4 but also 
for a first event in the general population.5 The mechanism underlying the association 
between body fat and altered autonomic function is not elucidated. We hypothesize 
that insulin resistance may be the underlying factor (Figure 1).
Obesity, especially abdominal obesity, is a risk factor for insulin resistance.6,7 Insulin 
resistance has also been associated with altered autonomic function in several cross-
sectional studies.8-12 Based on the results of these cross-sectional results, it remained 
unclear whether insulin resistance alters autonomic function, or vice versa. We however 
recently showed that autonomic function was not prospectively associated with the inci-
dence of type 2 diabetes mellitus during a median follow up of 9.2 years.13 This suggests 
that the autonomic nervous system may not be involved in the development of insulin 
resistance, and supports a pathophysiological mechanism in which insulin resistance is 
the first abnormality in obesity, resulting in sympathetic activation. This mechanism is 
further supported by the physiological reactions of the autonomic nervous system to 
infusions of blood glucose and insulin in humans.14,15
Therefore, our aim was to study the role of insulin resistance as a mechanism underlying 
the association between body fat and autonomic function (Figure 1). To that extent, 
we investigated the association between measures of body fat and parameters of auto-
nomic function and whether this association was mediated by insulin resistance.
METHODS
Study design and population
The Netherlands Epidemiology of Obesity (NEO) study is a population-based prospective 
cohort study comprising 6673 persons with an oversampling of individuals with a BMI 
≥ 27 kg/m². The study design and data collection of the NEO study have been described 
previously.16 In short, persons aged between 45 and 65 years with a self-reported BMI of 
27 kg/m² or higher were included between September 2008 and October 2012. In addi-
tion, all inhabitants aged between 45 and 65 years from one municipality (Leiderdorp) 
were invited irrespective of their BMI, allowing for a reference distribution of BMI.
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The baseline visit was performed in the NEO study centre in the Leiden University 
Medical Centre, during which an extensive physical examination was performed. The 
present study is a cross-sectional analysis of baseline measurements of the participants 
with a measurement of heart rate variability. We additionally excluded participants who 
were using oral glucose lowering medication or insulin. The NEO study was approved by 
the Medical Ethical Committee of the Leiden University Medical Centre and all partici-
pants gave their informed consent.
Data collection
Participants reported their highest level of education in ten categories according to the 
Dutch educational system. We grouped these data into low education (defined as no 
education, primary education or lower vocational training) versus high education (used 
as the reference category). Tobacco smoking was categorized into current, former or 
never (reference) smokers. Self-reported pre-existing cardiovascular disease was defined 
as myocardial infarction, angina, congestive heart failure, stroke, or peripheral vascular 
disease. Participants reported the frequency and duration of their physical activity using 
the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH) ques-
tionnaire. We calculated the total energy expended during physical activity in hours per 
week of metabolic equivalents (MET-h/week).
Body fat
We measured height and weight without shoes and one kilogram was subtracted to 
correct for the weight of clothing. Body Mass Index (BMI) was calculated by dividing 
the weight in kilograms by the height in meters squared. Total body fat was measured 
using a bio-impedance device (TBF-310, Tanita International Division, United Kingdom). 
We measured the circumference of the waist with a flexible tape in the middle of the 
distance between the lowest rib and the crista iliaca and used this as a measure of 
abdominal fat mass.
Insulin resistance
Venous blood was sampled after an overnight fast for at least 10 hours. Plasma glucose 
concentrations were measured with the enzymatic and colorimetric method (Roche 
Modular Analytics P800, Roche Diagnostics, Mannheim, Germany) and serum insulin 
concentrations were determined by an immunometric method (Siemens Immulite 2500, 
Siemens Healthcare Diagnostics, Breda, the Netherlands). We calculated the updated 
Homeostasis Model Assessment Insulin Resistance (HOMA-IR), a measure of insulin 
resistance which corresponds well to estimates of insulin resistance derived from the 
hyperinsulinemic euglycemic clamp, by entering fasting glucose and fasting insulin in a 
Microsoft Excel spreadsheet available on the internet.17
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Heart rate variability
Ten Actiheart devices, accelerometers combined with heart rate monitors, were ran-
domly distributed to NEO participants. We used the data from the heart rate monitor 
to calculate heart rate variability (HRV) parameters as indices of autonomic function. 
We selected only the Actiheart recordings with the least noise (<1%) for manual 
reparation and a valid estimation of heart rate variability. Two standard ECG electrodes 
(H98SG, Tyco Healthcare, Germany) were placed at the level of the second intercostal 
space, one electrode on the sternum and one ten centimetres to the left of the first 
electrode. The Actiheart was set up for a recording of four days. During this period, all 
interbeat intervals (IBIs) were stored in milliseconds. Participants were asked to perform 
their normal daily activities. For each participant with an Actiheart measurement, we 
excluded the first 12 hours of the recording because participants were not performing 
their normal activities during that period due to their visit to the NEO study centre. Then, 
we determined whether the quality of the IBI data was sufficient for heart rate variability 
analysis, by the detection of artefacts and non-sinus beats in the data. We calculated 
the percentage noise by dividing the number of artefacts and non-sinus beats by the 
total number of IBIs for each 24-h period using a moving average with a 1-h window. We 
selected the 24-h period with the least artefacts and non-sinus beats for reparation and 
subsequent HRV analysis, with a maximum of 1% artefacts/non-sinus beats. The raw IBI 
data were cleaned by removing artefacts and non-sinus beats using a semi-automatic 
Matlab program (designed by ACM). An overview of this procedure is shown in Figure 2. 
The Actiheart stores timings of all QRS complexes. Based on these timings, three types 
of non-sinus beats could be detected: missed QRS complexes, extra QRS complexes and 
QRS complexes that were detected too early (premature complexes) or too late (post-
mature complexes). We repaired non-sinus beats if they either added up to or could be 
divided in interpolated intervals that differed <5% from the mean of the ten preceding 
intervals. Artefacts and non-sinus beats that could not be repaired by the algorithm 
were deselected from the recordings by hand.
Heart rate variability parameters were calculated from the repaired IBI data according to 
a procedure that was described and applied previously.18,19 In short, HRV was calculated 
using a 5-min moving window and all valid 5-min values were averaged. We calculated 
the mean interbeat interval and standard deviation of all normal intervals (SDNN). Prior 
to spectral analysis of the recordings, the tachogram was processed with adjustment 
for linear trends, tachogram tapering and zero padding. A test of stationarity was per-
formed, and we excluded non-stationary episodes from the analysis. For calculation of 





In the NEO study individuals with a BMI of 27 kg/m² or higher were oversampled. To 
correctly represent associations in the general population, adjustments for the overs-
ampling of individuals with a BMI ≥ 27 kg/m² were made. This was done by weighting 
individuals towards the BMI distribution of participants from the Leiderdorp municipal-
ity, whose BMI distribution was similar to the BMI distribution of the general Dutch 
population.20 All results were based on weighted analyses.
Baseline characteristics were calculated as mean (standard deviation, SD), median (25th-75th 
percentile) or as percentage and were stratified for sex-specific tertiles of BMI. Differences 
in baseline characteristics between NEO participants with and without measurement of 
heart rate variability were tested with Student t-test for continuous variables and Chi-
square for categorical variables. The HOMA-IR and heart rate variability parameters were 
ln-transformed. Serum insulin concentrations below the detection limit of the assay (2.0 
mU/L) were imputed using multiple imputation methods for left censored data, with ten 
imputation datasets. We standardized the measures of body fat using sex-specific stan-
dard deviations. We used linear regression analysis to calculate regression coefficients of 
the associations between measures of body fat and HRV parameters (the total association, 
A+B in Figure 1). We adjusted for age, sex, tobacco smoking, ethnicity, education, physical 
activity, prevalent cardiovascular disease and cardiac medication. Regression coefficients 
were expressed as percentage difference in heart rate variability with 95% confidence 
intervals per weighted standard deviation of measures of body fat.
As a last step in our analyses, we included HOMA-IR into our model to investigate 
whether the total association between body fat and heart rate variability was mediated 
by insulin resistance (the indirect association, A in Figure 1). To that end, we calculated 
what percentage of the total association between body fat and heart rate variability was 




Figure 1. Hypothesized path diagram. Confounding factors: age, sex, tobacco smoking, ethnicity, educa-
tion, physical activity, prevalent cardiovascular disease and cardiac medication. A, indirect association be-
tween body fat and autonomic function (mediated by insulin resistance) B, direct association between 
body fat and autonomic function A + B, total association between body fat and autonomic function.
71
Insulin resistance, body fat and ANS function
4
mediated by HOMA-IR. The percentage mediated association was calculated as (1 - (di-
rect association / total association) * 100). The remaining coefficient after adjustment for 
HOMA-IR represents the direct association between body fat and heart rate variability, 
B in Figure 1.
Before adding HOMA-IR as mediator to the model, we tested for interaction between 
determinant and mediator by adding an interaction term of body fat and HOMA-IR to 
our linear regression model.
RESULTS
Baseline characteristics
From the 6673 participants included in the NEO study, an Actiheart device was carried 
by 955 participants to estimate physical activity. In 50 of this 955, the recording failed 
due to technical problems (e.g. broken battery, detached electrodes) or incorrect use 
by the participant (e.g. early removal). From the 905 remaining recordings, we selected 
485 recordings with maximum quality of IBI data (<1% artefacts) to use for heart rate 
variability analysis. After exclusion of participants with oral glucose lowering medication 
or insulin (n=19), the present analysis included 466 participants. Participants included 
in our study were more often men (56%) than excluded NEO participants (43%). Other 
24-hour recording 
Non-sinus beats Artefacts 
Missed QRS complex 
 
 














Manual deselection Reparation 
Non-sinus intervals add up 
to or can be divided in 
interpolated values <5% of 
the mean of ten preceding 
complexes? 
yes no 
Figure 2. Data processing of interbeat intervals for HRV analysis
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baseline characteristics did not differ between included and excluded participants 
(mean age was 56 (SD: 6) years in both groups, mean BMI was 27 (4) kg/m² in included 
participants and 26 (4) kg/m² in excluded participants, median HOMA-IR was 0.8 (25th-
75th percentile: 0.4-1.2) in included and 0.6 (0.4-1.1) in excluded participants). Table 1 
shows the baseline characteristics of the study population stratified by sex-specific 
tertiles of BMI.
Table 1: Baseline characteristics of NEO study participants with data on autonomic function, stratified by 
sex-specific tertiles of BMI (n=466)
BMI cut-off (kg/m²)
Men: 20-27 Men: 28-30 Men: 29-47
Variable Women: 19-28 Women: 29-31 Women: 32-47
Sex (% men) 57 59 43










Education (% low) 16 23 27
Physical activity (MET-hours/week) 121 (73-166) 123 (88-158) 108 (68-146)
Prevalent cardiovascular disease (%) 9 10 8
Use of antihypertensive medication (%) 19 32 40
Use of lipid lowering medication (%) 9 18 17



























Mean IBI (ms) 844 (788-901 805 (747-909) 816 (744-878)
SDNN (ms) 48 (41-56) 47 (39-57) 46 (36-55)
LF power (ms²) 928 (655-1300) 947 (609-1402) 775 (531-1144)
HF power (ms²) 218 (142-323) 242 (159-386) 232 (147-398)
HOMA-IR 0.5 (0.3-1.1) 1.0 (0.7-1.4) 1.3 (0.8-2.0)
Data are presented as mean (SD), median (25th-75th percentile) or percentage. Results were based on 
weighted analyses.
NEO, Netherlands Epidemiology of Obesity; BMI, Body mass index; MET, metabolic equivalent of task; IBI, 
interbeat interval; SDNN, standard deviation of all normal intervals; LF, low frequency; HF, high frequency; 
HOMA-IR, HOMA-index of insulin resistance
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Body mass index, insulin resistance and heart rate variability
The associations of BMI (per 4 kg/m² for men and 5 kg/m² for women) and parameters 
of heart rate variability are shown in Table 2. BMI was associated with mean IBI and LF 
power, with and without adjustment for confounding variables. There was also an asso-
ciation with SDNN, although not significant. We found no association between BMI and 
HF power. After additional adjustment for HOMA-IR as mediating factor, the association 
between BMI and parameters of heart rate variability attenuated. For mean IBI, 40% of 
the association was mediated by HOMA-IR, for SDNN 55% and for LF power 37% of the 
total association was mediated by HOMA-IR.
An interaction term of BMI and HOMA-IR was added to all models to test for interaction. 
For mean IBI the regression coefficient was 0.00025 (95% CI: −0.00243, 0.00292, P-value 
0.856), for SDNN the coefficient was −0.00014 (95% CI: −0.00775, 0.00749, P-value 0.972), 
for LF power 0.00166 (95% CI: −0.015555, 0.01887, P-value 0.849) and for HF power 
0.003379 (−.01342, 0.02100, P-value 0.665).
A sensitivity analysis excluding all participants with self-reported cardiovascular disease 
showed similar results. In the multivariate analyses and per standard deviation of BMI, 
the difference in mean IBI was −1.8 (95% CI: −2.9, −0.8), the difference in SDNN was −3.4 
(95% CI: −6.4, −0.6), in LF power was −8.0 (95% CI: −15.0, −1.4), and in HF power was 1.7 
(95% CI: −5.0, 8.0).
Total body fat and heart rate variability
Table 2 shows the associations between total body fat (per 6%) and parameters of 
heart rate variability. Total body fat was associated with mean IBI and non-significantly 
associated with SDNN and LF power. Total body fat did not associate with HF power. Of 
the total association between body fat and heart rate variability, 34% (mean IBI), 67% 
(SDNN) and 81% (LF power) was mediated by HOMA-IR.
An interaction term of total body fat and HOMA-IR was added to all model to test 
for interaction, showing regression coefficients of 0.0003192 (95% CI: −0.0014396, 
0.0020781, P-value 0.360) for mean IBI, −0.0013493 (95% CI: −0.005757, 0.0030584, P-
value 0.547) for SDNN, −0.0052708 (95% CI: −0.0145081, 0.0039666, P-value 0.262) for 
LF power and −0.0033135 (95% CI: −0.0137051,; 0.0070782, P-value 0.651) for HF power.
Repeating the analyses without participants with self-reported cardiovascular disease 
yielded similar results: per standard deviation of total body fat, the difference in mean 
IBI was −1.9 (95% CI: −3.0, −0.8), the difference in SDNN was −3.0 (95% CI: −6.2, 0.1), in LF 
power was −5.8 (95% CI: −11.7, 1.7), and in HF power was 0.8 (95% CI: −7.5, 8.5).
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Waist circumference and heart rate variability
The regression coefficients for the associations between waist circumference (per 11 
cm for men and 12 cm for women) and parameters of heart rate variability are shown 
in Table 2. Waist circumference was associated with mean IBI, SDNN and LF power. No 
association was found for HF power. The total association between waist circumference 
and heart rate variability was for 29% (mean IBI), 29% (SDNN) and 34% (LF power) medi-
ated by HOMA-IR.
The interaction term of waist circumference and HOMA-IR was non-significant in all 
models, mean IBI: −0.00019 (95% CI: −0.00119; 0.00081, P-value 0.713), SDNN: −0.00027 
(95% CI: −0.00309; 0.00256, P-value 0.854), LF power: 0.00045 (95% CI: −0.00598; 0.00688, 
P-value 0.890), HF power: 0.00414 (95% CI: −0.00311; 0.01138, P-value 0.262).
Table 2: Percentage difference (95% CI) in autonomic function per standard deviation of body fat measure 
(n=466)
Body fat measure (SD) Model Mean IBI SDNN LF power HF power
BMI (m: 4, w: 5 kg/m²)
Age and sex 
adjusted
−1.9 (−3.1, −0.8) −3.3 (−6.3, −0.4) −7.9 (−14.3, −1.8) −0.1 (−6.8, 6.2)
Multivariate¹ −1.6 (−2.7, −0.6) −2.7 (−5.5, 0.1) −7.0 (−13.5, −0.9) 0.3 (−5.9, 7.0)
+ HOMA-IR as 
mediator²
−1.0 (−2.2, 0.3) −1.2 (−4.2, 1.7) −4.4 (−11.0, 1.8) 3.9 (−3.1, 11.5)
Total body fat (6%)
Age and sex 
adjusted
−2.1 (−3.4, −0.8) −2.9 (−6.1, 0.1) −4.9 (−11.4, 1.3) 0.1 (−7.3, 8.2)
Multivariate¹ −1.9 (−3.0, −0.8) −2.4 (−5.4, 0.4) −4.3 (−10.8, 1.9) 0.8 (−6.7, 9.0)
+ HOMA-IR as 
mediator²
−1.3 (−2.5, 0.0) −0.8 (−3.9, 2.2) −0.8 (−7.4, 5.4) 4.9 (−4.3, 15.0)
Waist circumference 
(m: 11, w: 12 cm)
Age and sex 
adjusted
−2.3 (−3.6, −1.0) −4.5 (−7.8, −1.4) −8.5 (−15.9, −1.6) −1.2 (−9.1, 6.2)
Multivariate¹ −2.1 (−3.3, −0.9) −4.0 (−7.1, −0.9) −7.5 (−14.7, −0.8) −1.1 (−9.1, 6.3)
+ HOMA-IR as 
mediator²
−1.5 (−2.9, −0.1) −2.8 (−6.1, 0.4) −5.0 (−12.1, 1.7) 2.3 (−5.9, 11.1)
Results were based on weighted analyses. CI, confidence interval; SD, standard deviation; BMI, body mass 
index; IBI, interbeat interval; m, men; w, women; +, additionally adjusted for; SDNN, standard deviation of 
all normal intervals; LF, low frequency; HF, high frequency, HOMA-IR, Homeostatic model assessment of 
insulin resistance.
¹Multivariate model adjusted for: age, sex, smoking, ethnicity, education, physical activity, prevalent cardio-
vascular disease and cardiac medication
²Regression coefficients reflect the direct associations between body fat measures and measures of auto-
nomic function, after adjustment for HOMA-IR as mediating variable
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Repeating the analyses without participants with self-reported cardiovascular disease 
yielded similar results: per standard deviation of waist circumference, the difference in 
mean IBI was −2.4 (95% CI: −3.6, −1.2), the difference in SDNN was −4.8 (95% CI: −8.1, 
−1.6), in LF power was −8.3 (95% CI: −15.9, −1.1), and in HF power was −2.7 (95% CI: 
−11.3, 5.2).
DISCUSSION
In our middle-aged population, measures of body fat (BMI, waist circumference, total 
body fat) were associated with autonomic function measured as long term heart rate 
variability (mean NN interval, SDNN, LF power). These associations were most pro-
nounced for waist circumference. Depending on the parameter of body fat or heart 
rate variability, 29 to 81% of the total association seemed to be mediated by insulin 
resistance as assessed by HOMA-IR. There was no association between body fat and 
autonomic function, as measured with HF power.
The results on mean NN interval, SDNN and LF power are in line with previous studies 
on the association between body fat and parameters of sympathetic activation.1;21-23 
Our findings may add to those studies that insulin resistance is a possible mechanism 
underlying the association between body fat and autonomic function. An explanation 
for the lack of association with HF power may be that this spectral component is more 
indicative of the parasympathetic and not directly of the sympathetic outflow.(24)
A strength of the present study is the extensive phenotyping of the NEO participants 
including the measurement of total body fat and waist circumference, which more ac-
curately quantify body fat and abdominal fat accumulation than BMI does. However, our 
study also has limitations that need to be considered. The cross-sectional observational 
nature of our study is a limitation. We cannot exclude the possibility that our outcome 
(sympathetic activation) may have influenced our determinant (body fat), and so there 
may be reverse causation in our study. Another limitation is the use of the Homeostasis 
Model Assessment Insulin Resistance as a measure of insulin resistance instead of the 
hyperinsulinaemic euglycaemic clamp, but the correlation with the clamp is very high.25 
Also the use of the Actiheart for measurement of heart rate variability may be a limitation, 
but the agreement of Actiheart with the often used Holter electrocardiogram is high.26 
With regard to the statistical analysis, we used parametric mediation analysis assum-
ing linear models for the outcome and the mediator. This is a valid method to evaluate 
mediation in absence of mediator-outcome confounding and interaction between the 
exposure and the mediator under study.27 It needs to be taken into account that add-
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ing a possible mediating variable into a regression model could introduce bias in the 
estimation of the direct and indirect association if there is residual mediator-outcome 
confounding or interaction between determinant and mediator.27 In our study, we could 
only identify low-grade systemic inflammation as a potential residual confounder be-
tween insulin resistance (mediator) and autonomic function (outcome). Not adjusting for 
inflammation might have resulted in an overestimation of both the direct association of 
body fat with sympathetic activation and the association mediated by insulin resistance. 
However, it may well be that inflammation is not a common cause of insulin resistance 
and sympathetic activation, but rather an intermediate factor between insulin resis-
tance and sympathetic activation. In that case, adjusting for inflammation would result 
in an underestimation of the true association in our mediation analyses. To examine the 
presence of interaction between determinant and mediator, we tested for interaction by 
adding an interaction term of body fat measures and HOMA-IR to our linear regression 
models. All were non-significant, meaning that it is unlikely that adding HOMA-IR as a 
mediator to our models has resulted in bias in the estimation of the direct and indirect 
association. In addition, estimating direct and indirect associations is affected if the 
variability in the measurement of determinant and mediator is of different magnitude. 
In the NEO study, 100 participants were examined for the second time approximately 
three months after their baseline visit. From this repeated measurements, we calculated 
intraclass correlation coefficients (ICCs). The ICCs of body fat measures and HOMA-IR 
were both high (e.g. 0.940 (0.921-0.959) for total body fat and 0.749 (0.675-0.822) for 
HOMA-IR). This suggests that it is unlikely that a difference the variability in the measure-
ment of determinant and mediator has influenced our results.
Although cross-sectional, our results indicate that insulin resistance may be a mechanism 
underlying in the association between body fat and autonomic function (Figure 1). This 
finding is supported by evidence on three associations. First, excess body fat is a well-
established risk factor for insulin resistance.6,7 Second, the association between body 
fat and autonomic function has been shown in several previous studies.8-12 Adipose 
tissue secretes a number of hormones (e.g. leptin, adiponectin, resistin, visfatin) and 
inflammatory markers (e.g. TNF-α, IL-6). Thereby, the adipose tissue is able to directly 
stimulate the central sympathetic nervous system in the hypothalamus, or to induce 
a state of low-grade inflammation that can also stimulate the sympathetic nervous 
system.28 Third, insulin resistance has been associated with autonomic function in sev-
eral cross-sectional studies.8-12 We know from experimental studies that higher levels of 
circulating insulin elevate sympathetic outflow both in the euglycaemic or hypergly-
caemic state.14,15 The stimulation of the sympathetic nervous system seems at least in 
part attributable to the central action and peripheral action of insulin.29 However, also 
after the diagnosis of diabetes (and the onset of beta-cell failure), autonomic function 
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deteriorates.30 Therefore, it seems unlikely that the impairment of autonomic function 
is due to hyperinsulinaemia alone. Likely, also the hyperglycaemia and an abundance of 
advanced glycation end-products in insulin resistant individuals play a role in inducing 
autonomic dysfunction by damaging the nerves or interfering with chemical signalling.
In conclusion, in this cross-sectional study body fat was associated with autonomic 
function measured as heart rate variability. This association may at least partially be 
mediated by insulin resistance. Future studies should investigate whether a reduction in 
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Heart rate variability (HRV) is associated with cardiovascular disease (CVD) in indi-
viduals with known CVD. It is less clear whether HRV is associated with a first car-
diovascular event. Therefore, we performed a meta-analysis to study the association 
between HRV and incident cardiovascular events in populations without known CVD.
Methods and results
We performed a meta-analysis and dose-response meta-regression of studies assess-
ing the association between HRV and CVD. We searched Pubmed, Embase, Web of 
Science, Cochrane library, ScienceDirect and CINAHL up to December 2011 for eli-
gible studies. We selected studies that used the standard deviation of the normalized 
N-N interval (SDNN), low frequency (LF) or high frequency (HF) spectral component 
as a measure of HRV. Primary outcomes were (non)fatal cardiovascular events.
Eight studies with a total number of 21988 participants were included. The pooled 
relative risk comparing the lowest level to the highest level of SDNN was 1.35 (95% 
CI 1.10, 1.67). The pooled relative risks for LF and HF were 1.45 (95% CI 1.12, 1.87) 
and 1.32 (95% CI 0.96, 1.81), respectively. In a meta-regression, the predicted RR of 
incident CVD of the 10th and 90th HRV (SDNN) percentile compared to the 50th 
percentile were 1.50 (95% CI 1.22, 1.83) and 0.67 (95% CI 0.41, 1.09).
Conclusion
In conclusion, low HRV is associated with a 32-45% increased risk of a first cardiovas-
cular event in populations without known CVD. An increase in SDNN of 1% results in 
an approximately 1% lower risk of fatal or non-fatal CVD.
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INTRODUCTION
Cardiovascular disease (CVD) is one of the main causes of morbidity and mortality in 
industrialized countries. Cardiac autonomic dysfunction is a risk factor for the develop-
ment of CVD that can be measured non-invasively using heart rate variability (HRV).1 
Physiologically, HRV is thought to be the result of adaptive changes in heart rate caused 
by the sympathetic and parasympathetic nervous system, with the purpose to buffer 
blood pressure.2 Less compensatory change (low HRV) suggests a decreased adaptive 
autonomic nervous system and is thought to be associated with increased morbidity. 
HRV has long been known to be associated with morbidity and mortality after myo-
cardial infarction.3 This finding has been confirmed in many studies.4, 5 Besides acute 
myocardial infarction and cardiac death, also occurrences of congestive heart failure 
and arrhythmias have been associated with reduced HRV.6, 7
Although HRV is associated with cardiovascular events in individuals with known CVD, 
fewer studies have been published on the association between HRV and the risk of 
CVD in a population without known CVD. Therefore, the aim of this meta-analysis was 




A systematic literature search was performed, aimed at identifying epidemiological 
studies with data on the association between HRV and CVD. We searched the elec-
tronic databases Pubmed, Embase, Web of Science, Cochrane library, ScienceDirect and 
CINAHL from their inception up to December 2011. No language restriction was set in 
advance. The reference lists of all relevant identified articles were screened for additional 
potentially relevant articles.
Eligibility criteria
Initial selection of studies by title and abstract was performed by two reviewers (S.H. 
and K.B.G.) independently. Disagreements were resolved by consensus. Population-
based studies in adults assessing the association between HRV and CVD were eligible 
for inclusion. Abstracts of meetings and unpublished results were not eligible. Since the 
aim of the study was to assess the association between HRV and incident CVD, cohorts 
restricted to patients with CVD at baseline were excluded. Furthermore, we did not in-
clude studies in our meta-analysis if they presented a measure of HRV that was only used 
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in one or two studies. To be included, studies should have expressed the association 
between HRV and CVD as relative risks (RRs) (risk ratios, odds ratios or hazard ratios). 
Maximally adjusted RRs and confidence intervals (CIs) for the association between HRV 
and CVD were extracted. Data were extracted in duplicate (S.H. and K.B.G.), using a 
standard data extraction sheet.
Measures of HRV
HRV can be expressed using several measures. In order to calculate different measures 
of HRV, intervals between adjacent normal R waves (NN intervals) are measured. The 
standard 12-lead ECG is a common method to measure these intervals. In the time 
domain analyses, a variety of statistical variables are calculated from NN intervals. The 
most commonly used time domain variables are the standard deviation of all N-N inter-
vals (SDNN) and the square root of the mean of the sum of the squares of differences 
between adjacent R-R intervals (RMSSD).8
The frequency domain is another method used to calculate HRV, of which the low 
frequency (LF) and the high frequency (HF) spectral components are common mea-
sures. In the frequency domain method, cyclic fluctuations of RR intervals are quantified 
by the frequency of the fluctuation using Fourier transformation or auto regression 
spectral analysis.1 Typically, HF fluctuations are thought to be caused by respiration and 
are effectuated by parasympathetic outflow. LF fluctuations are probably the result of a 
blood pressure resonance phenomenon mediated by the baroreflexes and are effectu-
ated by both sympathetic and parasympathetic fluctuations in outflow.2, 9
Study endpoints
The outcome of interest was the occurrence of a first fatal or nonfatal cardiovascular 
event. In this meta-analysis we defined fatal or non-fatal CVD as myocardial infarction, 
coronary revascularization procedures, hospitalization for unstable angina pectoris, 
congestive heart failure, arrhythmia (atrial/ventricular), arterial peripheral vascular 
disease, stroke (ischemic/haemorrhagic) or death from these events.10
Risk of bias assessment
For the aim of the present meta-analysis, risk of bias assessment focused on design 
elements that could potentially bias the association between HRV and CVD: (i) ascer-
tainment that the outcome of interest was not present at baseline, (ii) adequacy of 
follow up (loss-to-follow up of less than five percent was considered adequate), (iii) 
effect estimates having been adjusted for potential confounding factor, (iv) adequacy of 
endpoint verification. Endpoint verification was considered adequate when diagnoses 
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were confirmed using medical records or death certificates. Self-report was considered 
to present a high risk of bias.
Statistical analyses
According to the data available in included articles, HRV was categorized based on 
percentiles (median, tertiles or quartiles). When papers presented their results using 
an author defined cut-off value, we calculated the accompanying percentiles under the 
assumption of a normal distribution of HRV. If authors calculated a RR for one SD change 
in HRV, we recalculated this RR for categories based on quartiles assuming a normal dis-
tribution of HRV and a linear association on a logarithmic scale between HRV and CVD. 
For each study the highest HRV category was used as the reference and for all studies 
the lowest HRV category was compared with the highest category. We performed a 
random effects meta-analysis based on maximally adjusted relative risks of the highest 
versus the lowest categories and their accompanying standard error. Heterogeneity was 
quantified using the I² statistics. We performed two sensitivity analyses; one excluding 
populations with only diabetes patients and one separating the different measurement 
durations of HRV (short measurements of 10 seconds to three minutes versus longer 
measurements of 24 hours).
Secondly, we performed a meta-regression to assess a dose-response slope for the 
association between HRV and CVD. We used a random effects model to take the between-
study variation into account. For each individual study, a weight was calculated based 
on the standard error. The 50th percentile was used as the reference category.11 Based 
on the slope from the random effects regression, we predicted risk ratios comparing the 
10th and the 90th percentile to the 50th percentile. Statistical analyses were performed 
with Stata Statistical Software (Statacorp, USA), version 12.
RESULTS
Literature search
We identified 3613 publications by database search (PubMed, n=2062; EMBASE, n=516; 
Web of Science, n=83; ScienceDirect, n=9; CINAHL, n=152; Cochrane, n=791). After 
checking for duplicates, we retrieved 3395 unique publications. After screening of title 
and abstract, 3309 studies were excluded and 86 papers were retrieved for detailed 
assessment. Sixty-three papers did not meet the eligibility criteria, 23 studies were 
assessed in duplicate for inclusion. Of these papers, several were based on the same 
cohort. Four papers were based on the ARIC study12-15, two on the Framingham Heart 
study16, 17, three on the Cardiovascular Health study18-20, three on the Ohasama study21-23 
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and two on a cohort from Finland.24, 25 To avoid multiple inclusions of the same study 
subjects, for each study we only included the paper with the largest sample size in our 
meta-analysis. As a result, nine papers were excluded. Furthermore, six studies were 
excluded because they presented a measure of HRV that was only used in one or two 
studies.23, 26-30 Finally, a total of eight studies were included in this meta-analysis that 
used SDNN, LF or HF as a measure of HRV (Figure 1).
Study characteristics
Characteristics of the included studies are presented in Table 1. All included studies 
were prospective cohort studies. Two cohorts presented data separately for diabetics 
and non-diabetics.15, 31 A total of 21988 participants were included in the analyses. The 
size of the study populations ranged from 159 to 11647.15, 31 The percentage of women 
varied from 0% to 64%.32, 33 Mean follow-up duration ranged from 3.5 to 15 years.17, 32 
Four studies defined their endpoint as cardiovascular death.25, 32-34 Other studies used a 
combined endpoint, namely: congestive heart failure, hospitalization for angina pectoris 
and cardiovascular death17; MI, coronary revascularization and cardiovascular death15; 
MI, arterial peripheral vascular disease, stroke, congestive heart failure, hospitalization 
3613 potentially relevant 
publications identified from 
electronic search
3395 unique publications 
retrieved
86 publications retrieved for 
detailed assessment
23 studies assessed in 
duplicate for inclusion
8 studies included in the meta-
analysis
218 duplicates excluded
3309 publications excluded by 
title and abstract
63 studies did not meet 
eligibility criteria
9 studies excluded to avoid multiple inclusions of 
the same cohorts 
6 papers excluded for presenting a HRV 
measurement used in only 1 or 2 studies
Data on: 
-Standard deviation of NN intervals (8 studies) 
-Low frequency spectral component (4 studies) 
-High frequency spectral component (4 studies)
Figure 1. Flow chart of study selection
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for angina pectoris and cardiovascular death20 and MI, coronary revascularization, arte-
rial peripheral vascular disease, stroke and cardiovascular death.31
Risk of bias
CVD at baseline was assessed in all studies except in one that did not give a clear 
description of this assessment.32 Six studies mentioned loss-to-follow-up; in five of 
them this was <5%.15, 20, 31-33 The other study mentioned a loss-to-follow up of 5.6%.34 
Two studies did not give any information about loss-to-follow up.17, 25 HRV was assessed 
prior to the outcome in all eight papers. The instrument used to measure NN intervals 
was clearly described in all studies, but one study lacked data on the assessment of 
HRV from the recordings.34 Diagnosis of CVD was verified by medical records, death 
certificates or general practitioner’s registries in all studies. Seven studies adjusted for 
potential confounders, one study only presented unadjusted risk estimates.20 For details 
of adjustments see Table 1.
Standard deviation of NN intervals and CVD
All eight studies reported on the association between SDNN and fatal and nonfatal 
CVD. Two studies presented data for two separate groups of patients (diabetic and non-
diabetic). The reported relative risks of fatal or non-fatal CVD comparing low to high HRV 
ranged from 0.78 to 1.99. One study reported a relative risk below 1.034 and one study an 
estimate of 1.02.33 In the other six studies the relative risks were all higher than 1.26. In a 
random effects meta-analysis, a low SDNN was associated with an increased risk of fatal 
or non-fatal CVD: RR 1.35 (95% CI 1.10, 1.67). The I₂ of the analysis was 60.2% (Figure 2).
We performed a sensitivity analysis excluding the risk estimates of the two populations 
with diabetes.15, 31 This analysis showed a similar pooled relative risk of fatal or non-
fatal CVD of 1.32 (95% CI 1.04, 1.68). Furthermore, we distinguished between different 
measurement durations. This analysis indicated effect modification of the association 
between HRV and fatal or non-fatal CVD by duration of the measurement, although the 
numbers of studies per subgroup were small. The association was stronger for HRV mea-
sured over 2-24 hours (RR for CVD 1.70, 95% CI 1.33, 2.17) than HRV measurements over 
2-3 minutes (RR 1.35, 95% CI 1.08, 1.69) or measurements shorter than approximately 30 
seconds (RR 0.97, 95% CI 0.74, 1.28).
Finally, for studies that defined their outcome solely as cardiovascular death (n=4) 
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Low frequency spectral component and CVD
Four studies used the LF spectral component as a measure of HRV, with a total number 
of 15215 participants. All these studies used combined endpoints to define CVD. Two 
studies presented results for the diabetic as well as the non-diabetic population.15, 31 The 
RR for the lowest LF compared to the highest LF category ranged from 1.01 to 1.77. The 
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Figure 2. Meta-analysis comparing risk of fatal and non-fatal cardiovascular disease in low versus high 
heart rate variability measured as standard deviation of NN intervals







































1.5 2 4 8
Figure 3. Meta-analysis comparing risk of fatal and non-fatal cardiovascular disease in low versus high 
heart rate variability measured as low frequency spectral component
Chapter5
90
pooled RR was 1.45 (95% CI 1.12, 1.87), indicating that a low LF was associated with a 
higher risk of fatal and non-fatal CVD. I₂ of this analysis was 50.4% (Figure 3).
High frequency spectral component and CVD
The HF spectral component was used as a measure of HRV in the same studies that 
reported on the LF spectral component. The RRs for the association between HF and 
HRV ranged from 0.83 to 1.87. Lower HF was associated with a higher risk of fatal and 
non-fatal CVD (RR: 1.32, 95% CI: 0.96, 1.81), I₂=67% (Figure 4).
Meta-regression of SDNN and CVD
We performed a meta-regression to assess a dose-response relationship between HRV 
and CVD for studies with SDNN as a measure for HRV. We accepted a linear relationship 
between HRV and CVD, since the model including a quadratic term did not perform 
better than the linear model (p from likelihood ratio = 0.75). The random effects meta-
regression showed an increasing risk of cardiovascular events for lower HRV (slope = 
−0.01, p=0.011). The predicted RR of fatal or non-fatal CVD of the 10th HRV percentile 
compared with the 50th percentile was 1.50 (95% CI 1.22, 1.83); the predicted RR of the 
90th percentile compared with the 50th percentile was 0.67 (95% CI 0.41, 1.09). These 
results indicate that an increase in SDNN of one percent results in an approximately one 
percent lower risk of the development of fatal or non-fatal CVD (Figure 5).
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Figure 4. Meta-analysis comparing risk of fatal and non-fatal cardiovascular disease in low versus high 
heart rate variability measured as high frequency spectral component
91
Heart rate variability and first cardiovascular event
5DISCUSSION
Main results
The present meta-analysis was performed to assess the association between HRV and 
a first cardiovascular event in a population without known CVD. The study showed that 
individuals with low HRV have approximately a 40% increased risk of fatal or non-fatal 
CVD compared with individuals with high HRV. Our study is the first meta-analysis and 
dose-response meta-regression to show that low HRV is also associated with CVD in a 
population without known CVD.
Strengths and limitations
The present study has several strengths. First, studies included in our analyses were 
cohorts with a large total number of participants, which adds to the robustness of the 
results. Outcome ascertainment at baseline and verification of endpoints were consid-
ered adequate in the majority of the studies. Furthermore, our findings were consistent 





















0 20 40 60 80 100
Percentile of HRV
Figure 5. Dose-response meta-regression for the association between heart rate variability measured as 
standard deviation of NN intervals and fatal and non-fatal cardiovascular disease
Chapter5
92
A potential weakness of our study is the adjustment for possible confounders in some 
studies. One study did not present adjusted RRs.20 Furthermore, none of the studies 
adjusted for physical activity and respiration, whereas only one study adjusted for mean 
heart rate. Studies have been published that suggest that these factors should be taken 
into account.35-37
Another potential limitation is the limited number of included studies, especially in the 
analysis of the LF and HF spectral component (n=4). Despite the low number of studies 
however, the direction and magnitude of the pooled RRs of fatal and non-fatal CVD for 
these two measures of HRV were in line with the pooled risk of the studies using SDNN.
Clinical implications and future research
HRV is the result of changes in heart rate caused by fluctuations in sympathetic and para-
sympathetic outflow. These fluctuations vary in length. An example of slow fluctuations 
is circadian variation, whereas faster fluctuations in heart rate are due to sympathetic 
and parasympathetic responses to minor hemodynamic changes. Respiration causes 
a cyclic variation in intrathoracic pressure and thereby venous return, which leads to 
fluctuations in cardiac output and arterial blood pressure. The arterial baroreflex reacts 
to these fluctuations in arterial blood pressure by producing fluctuations in parasym-
pathetic and sympathetic autonomic outflow that induce compensatory modulations 
in peripheral resistance, cardiac contractility and heart rate.2, 9 Reduced compensatory 
change (low HRV) suggests a less adaptive autonomic nervous system. However, the 
physiological interpretation of HRV, especially in the LF spectral band, remains contro-
versial. Whereas the dependence of HF power on respiration-related parasympathetic 
outflow has repeatedly been confirmed, there are indications that LF power is not a 
measure of sympathetic outflow. Some investigators have found that LF is a reflection of 
baroreflex function instead of cardiac sympathetic innervation.38
It is known that after a cardiovascular event, individuals with lowered HRV have an 
increased risk of cardiovascular morbidity and mortality compared to subjects with 
high HRV.3-7, 39, 40 These results indicate that a less adaptive autonomic nervous system 
is a marker of cardiovascular risk. Furthermore, it shows that the autonomic nervous 
system becomes less sensitive for minor hemodynamic changes after a first cardiac 
event, which might be a direct cause of a secondary cardiovascular event. Our meta-
analysis shows that HRV is also associated with cardiovascular morbidity and mortal-
ity in the general population. This suggests that decreased fluctuations in heart rate, 
caused by inadequate autonomic nervous system circulatory control, is also a sign of 
less favourable health in otherwise healthy individuals. Furthermore, our results seem 
to show effect modification of the association between HRV and CVD by duration of the 
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measurement. This finding might indicate that a decrease in long term fluctuations in 
heart rate is more important for the risk of CVD than short term fluctuations. However, 
since the numbers our stratified analyses are very small, this result must be interpreted 
with caution.
A possible mechanism underlying our findings is low grade inflammation. It has been 
suggested that autonomic imbalance could activate inflammation by influencing the 
bone marrow and lymphoreticular system.41 Increased inflammation is associated with 
higher risk of CVD. Another possible explanation for the association between HRV and a 
first cardiovascular event is that individuals with low HRV already suffer from subclinical 
or silent cardiovascular disease. These individuals are expected to have both a lower 
HRV and a higher risk of a following CVD event.
HRV measurement is inexpensive, easy to assess and non-invasive. It is potentially a useful 
predictor of CVD in both healthy and diseased individuals. Improved identification of in-
dividuals at risk for the development of CVD may result in more targeted and adequate 
prevention strategies. Future research should focus on the clinically applicability of the 
existing knowledge about HRV, for example by aiming to find cut-off points and deter-
mine the value of HRV in addition to established risk factors. When investigating HRV for 
risk stratification in clinical practice, the possible influence of respiration and mean heart 
rate should be taken in account.
Conclusion
In conclusion, our meta-analysis shows that individuals with a low HRV have 32-45% 
increased risk of CVD compared with individuals with a high HRV. Our study is the first 
meta-analysis to show that low HRV is also associated with a first cardiovascular event 
in a population without known CVD. It therefore supports the hypothesis that cardiac 
autonomic dysfunction is associated with a higher risk of CVD. Whether HRV might be 
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Mouse studies have revealed an important role for the sympathetic nervous system (SNS) 
in lipid metabolism, which may offer novel therapeutic modalities to treat dyslipidaemia. 
However, the role of the SNS in lipid metabolism in humans is insufficiently studied. 
Therefore, we aimed to study the association between SNS activation, measured as heart 
rate or heart rate variability, and serum triglyceride, non-high-density lipoprotein concen-
trations, high-density lipoprotein concentrations, and intrahepatic triglyceride content.
Methods
This is a cross-sectional analysis of baseline data of the Netherlands Epidemiology of 
Obesity study. Heart rate was estimated from a 10 second 12-lead electrocardiogram and 
parameters of heart rate variability were calculated over 24 hours. Fasting serum choles-
terol concentrations were measured. Serum triglycerides were measured after fasting and 
30 and 150 min after a liquid mixed meal. Intrahepatic triglyceride content was measured 
by ¹H-magnetic resonance spectroscopy. We performed linear regression analyses and 
adjusted for age, sex, smoking, education, physical activity, meal time, heart rate lowering 
medication, lipid lowering medication, body mass index, total body fat and HOMA-IR.
Results
After exclusion of individuals with missing data (n=496), 6174 participants were included: 
44% men, mean (SD) age: 56 (6) years and mean BMI 26 (4) kg/m². Per 10 beats/min, 
total cholesterol concentration was 0.06 mmol/L (95% CI: 0.02, 1.10) higher and fasting 
serum triglyceride concentration was 5.8% (3.9, 7.8) higher. Resting heart rate was not 
associated with serum HDL-cholesterol or LDL-cholesterol concentrations. Postprandial 
triglyceride concentrations were 5.2% (3.5, 6.9) higher 30 minutes, and 4.4% (2.6, 6.3) 
higher 150 minutes after the liquid mixed meal. Intrahepatic triglyceride content was 
13.1% (7.7, 18.7) higher after adjustment for confounding factors. Associations with heart 
rate variability were similar.
Conclusion
SNS activation, measured as higher resting heart rate or lower heart rate variability, was 
associated with higher fasting total cholesterol and higher serum triglyceride concentra-
tions, and with higher intrahepatic triglyceride content. These results imply that the SNS 
is involved in lipid metabolism in humans, and that dyslipidaemia may be targeted by 
lowering SNS activation




The autonomic nervous system is an involuntary nervous system with a sympathetic 
and a parasympathetic branch. Heart rate is a reflection of autonomic nervous system 
function (sympathovagal balance) that can be estimated as the intrinsic heart rate multi-
plied by a sympathetic factor and a vagal factor.1, 2 Heart rate variability is a manifestation 
of activity of the baroreflex, which purpose is to buffer blood pressure by adaptions in 
sympathetic and parasympathetic outflow.3, 4 A shift in sympathovagal balance towards 
increased activity of the sympathetic nervous system (SNS) results in a higher heart rate 
and lower heart rate variability, which are associated with both cardiovascular risk factors 
and cardiovascular events.5-8 The mechanism underlying the increased cardiovascular 
risk due to SNS activation has not been elucidated. Since dyslipidaemia is a prominent 
risk factor for cardiovascular disease, alterations in lipid metabolism possibly play a role.
Lipid metabolism is influenced by the SNS in several ways. First, the SNS innervates the 
adipose tissue.9 Sympathetic stimulation of adipose tissue induces intracellular lipoly-
sis, thereby increasing the amount of glycerol and free fatty acids in the circulation.10 
Second, sympathetic stimulation of the liver enhances hepatic de novo lipogenesis.11 
Experimental studies showed that selective sympathetic denervation of the liver in rats 
decreased both hepatic lipogenesis and decreased hepatic very low-density lipoprotein 
(VLDL)-triglyceride secretion.12, 13 This indicates that activation of the SNS stimulates 
both lipogenesis and the secretion of VLDL-triglycerides in the liver.
In healthy individuals, activation of the SNS is an adaptive response, aimed at 
temporarily providing lipids as a substrate for energy metabolism in muscles during 
fasting or ‘flight-fight-or-fright actions’. However, chronic SNS activation may result in 
an prolonged increased lipid production, by stimulation of lipolysis in adipose tissue 
and of de novo lipogenesis in the liver, even if lipids are not necessary as a substrate 
for energy metabolism. This may result in higher fasting serum triglycerides and non-
high-density lipoprotein (non-HDL) cholesterol concentrations and possibly a lower 
HDL-cholesterol concentration in the circulation (Figure). Some previous studies have 
reported these associations.14-16 However, no previous study has investigated the as-
sociation between heart rate and postprandial serum triglyceride concentrations after 
a mixed meal. Furthermore, in addition to an increased concentration of lipids in the 
circulation, the chronic activation of the SNS may also result in accumulation of lipids in 
the liver.17 Evidence on this association is also lacking. Therefore, we hypothesized that 
SNS activation is associated with a disadvantageous lipid metabolism, specifically with 
triglyceride levels in the circulation and the liver. To this extent, we studied the associa-
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tions of resting heart rate and heart rate variability with fasting and non-fasting serum 
lipid concentrations and intrahepatic triglyceride content in a population-based study.
METHODS
Study design and population
The Netherlands Epidemiology of Obesity (NEO) study is a population-based prospective 
cohort study of 6673 individuals aged 45 to 65 years with an oversampling of individuals 
with a BMI ≥ 27 kg/m². The study design and data collection of the NEO study have been 
described previously.18 In short, persons with a self-reported BMI of 27 kg/m² or higher 
were included between September 2008 and October 2012 from the greater area of 
Liver 











Figure. Sympathetic control of lipid metabolism
SNS=sympathetic nervous system; TG=triglyceride; FFA=free fatty acid; VLDL=very low-density lipoprotein; 
LDL=low-density lipoprotein
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Leiden, the Netherlands. In addition, all inhabitants from one municipality (Leiderdorp) 
were invited irrespective of their BMI, allowing for a reference distribution of BMI. The 
present study is a cross-sectional analysis using the baseline measurements of the NEO 
study.
Participants were invited for a baseline visit at the NEO study centre of the Leiden 
University Medical Centre. Prior to this study visit, participants fasted overnight for at 
least 10 hours and completed a questionnaire on demographic, lifestyle, and clinical 
data in addition to questions on diet and physical activity. The participants were asked 
to bring all their current medication to the study centre. At the baseline visit, the partici-
pants underwent an extensive physical examination, including fasting and postprandial 
blood sampling, and a resting standard 10-second electrocardiogram (ECG). Heart rate 
variability and intrahepatic triglyceride content were measured in random subsamples 
of the baseline population. The NEO study was approved by the Medical Ethical 
Committee of the Leiden University Medical Centre. Before inclusion, all participants 
gave their informed consent.
Data collection
Participants reported their highest level of education in 10 categories according to the 
Dutch educational system. We defined low education as no education, primary educa-
tion or lower vocational training) and used high education as the reference category in 
the analyses. Self-identified ethnicity of participants was reported in eight categories 
that we grouped into white (reference) and other. Tobacco smoking was categorized 
into current, former or never (reference) smokers. We estimated alcohol intake in grams 
per week by questionnaire. We measured physical activity using the Short Questionnaire 
to Assess Health-enhancing physical activity questionnaire and calculated the metabolic 
equivalent of task (MET) hours per week.19
We measured height and weight without shoes and one kilogram was subtracted to 
correct for the weight of clothing. Body Mass Index (BMI) was calculated by dividing 
the weight in kilograms by the height in meters squared. Total body fat was measured 
with a bio-impedance device (TBF-310, Tanita International Division, United Kingdom). 
Blood was sampled from the antecubal vein after an overnight fast of at least 10 hours, 
and 30 minutes and 150 minutes after consumption of a liquid mixed meal (400 mL 
containing 600 kcal, 16 % of energy (En%) derived from protein, 50 En% carbohydrates, 
and 34 En% fat). In the fasting blood samples, serum concentrations of triglycerides and 
total cholesterol were measured with the colorimetric method and HDL-cholesterol 
concentrations were measured with the homogenous HDLc method (Roche Modular 
Analytics P800, Roche Diagnostics, Mannheim, Germany). LDL-cholesterol concentra-
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tions were calculated with the Friedewald formula.20 Serum triglyceride concentrations 
were also measured 30 minutes and 150 minutes after the liquid mixed meal. Plasma 
glucose concentrations were measured with the enzymatic and colorimetric method 
(Roche Modular Analytics P800, Roche Diagnostics, Mannheim, Germany) and serum 
insulin concentrations were determined by an immunometric method (Siemens Im-
mulite 2500, Siemens Healthcare Diagnostics, Breda, the Netherlands). Serum insulin 
concentrations below the detection limit of the assay (2.0 mU/L) were imputed using 
multiple imputation methods for left censored data, with 10 imputation datasets.21 We 
calculated the updated Homeostasis Model Assessment Insulin Resistance (HOMA-IR), 
by entering fasting glucose and fasting insulin in a Microsoft Excel spreadsheet available 
on the internet.22
Heart rate and heart rate variability
To estimate the heart rate, a resting 12-lead ECG was obtained using a Mortara Eli-350 
electrocardiograph (Mortara Instrument Inc., Best, Netherlands). Mean resting heart rate 
was calculated using the Matlab-based program BEATS.23
The Actiheart device, an accelerometer combined with a heart rate monitor (CamNtech 
Ltd, Cambridge, United Kingdom), was worn by a random subsample (14%) of the base-
line population. We used the data from the heart rate monitor to calculate heart rate 
variability parameters. We selected only the Actiheart recordings with the least noise 
(<1%) for manual reparation and a valid estimation of heart rate variability. The heart 
rate data were processed to remove artefacts and non-sinus beats, and consequently 
heart rate variability was calculated over a 24 hour period according to a procedure that 
was described and applied previously.2, 24, 25 In short, heart rate variability was calculated 
using a 5-minute moving window and all valid 5-minute values were averaged. We 
calculated the mean interbeat interval, the standard deviation of all normal intervals 
(SDNN) and the root mean square of the successive differences (RMSSD). Prior to spec-
tral analysis of the recordings, the tachogram was processed with adjustment for linear 
trends, tachogram tapering and zero padding. A test of stationarity was performed, and 
we excluded non-stationary episodes from the analysis. For calculation of low frequency 
power (LF power) and high frequency power (HF power), a fast Fourier transformation 
was employed.
Intrahepatic triglyceride content
A random subsample (35%) of participants without contra-indications underwent 
proton (1H)-MR spectroscopy of the liver to assess hepatic triglyceride content. All 
imaging was performed on an MR system operating at a field strength of 1.5 Tesla 
(Philips Medical Systems, Best, Netherlands). Hepatic ¹H-MR spectra were obtained as 
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described previously.26 In short, ¹H-MRS (magnetic resonance spectroscopy) of the liver 
was performed with an 8 mL voxel positioned in the right lobe of the liver, avoiding 
gross vascular structures and adipose tissue depots. Sixty-four averages were collected 
with water suppression. Spectra were obtained with an echo time of 26 milliseconds and 
a repetition time of 3000 milliseconds. Data points (1024) were collected using a 1000 
Hz spectral line. Without changing any parameters, spectra without water suppression, 
with a repetition time of 10 seconds, and with four averages were obtained as an internal 
reference. ¹H-MRS data were fitted using Java-based magnetic resonance user interface 
software (jMRUI version 2.2, Leuven, Belgium), as described previously.27 Intrahepatic 
triglyceride content relative to water was calculated as (signal amplitude of triglyceride) 
/ (signal amplitude of water) * 100.
Statistical analyses
In the NEO study, individuals with a BMI of 27 kg/m² or higher were oversampled. To 
correctly represent associations in the general population, adjustments for the oversam-
pling of individuals with a BMI ≥ 27 kg/m² were made.28 This was done by weighting in-
dividuals towards the BMI distribution of participants from the Leiderdorp municipality, 
whose BMI distribution was similar to the BMI distribution of the general Dutch popula-
tion.29, 30 All results were based on weighted analyses. Consequently, the results apply to 
a population-based study without oversampling of participants with a BMI ≥ 27 kg/m².
Baseline characteristics were expressed as mean (standard deviation), median (25th- 75th 
percentiles) or as percentage by tertiles of heart rate. We performed weighted linear 
regression analysis with heart rate per 10 beats/min or heart rate variability per stan-
dard deviation as a determinant. As outcome variables we used total cholesterol, LDL-
cholesterol, HDL-cholesterol, fasting and postprandial (30 min and 150 min) serum tri-
glyceride concentrations (mmol/L) and intrahepatic triglyceride content (%). The serum 
triglyceride concentrations and intrahepatic triglyceride content were ln-transformed. 
Regression coefficients were expressed as mmol/L or as percentage difference with 95% 
confidence intervals for ln-transformed variables. We adjusted our results for age, sex, 
tobacco smoking, education, physical activity, heart rate lowering medication and lipid 
lowering medication. The analyses including intrahepatic triglyceride content were also 
adjusted for time since ingestion of the mixed meal and alcohol intake. Additionally we 





The NEO study included 6673 participants. We consecutively excluded participants 
with missing data on heart rate (n=89), lipid concentrations (n=44), education (n=64), 
physical activity (n=116), body composition (n=31), HOMA-IR (n=148) and other con-
founders (n=7). The main analyses therefore included 6174 participants. Compared with 
excluded participants, included participants were more often men (44% versus 40%). 
Other variables were comparable: age was 56 (6) years and BMI was 26 (4) kg/m² in both 
excluded and included participants. Total cholesterol was 5.6 (1.1) mmol/L in excluded 
and 5.7 (1.1) mmol/L in included participants and fasting serum triglyceride concentra-
tion was 1.1 (0.8) mmol/L versus 1.2 (0.8) mmol/L.
Table 1 shows the weighted baseline characteristics of the 6174 participants included in 
our analyses, stratified by tertiles of heart rate. Participants with a higher heart rate had 
more body fat and were more often women.
Table 1 Characteristics of the study population by tertiles of heart rate
Beats/min 30-59 60-67 68-157
Age (year) 55 (6) 55 (6) 56 (6)
Sex (% men) 51 41 39
BMI (kg/m²) 26 (4) 26 (4) 27 (5)


















Education level (% low) 17 19 23
MET hour/week 124 (84-161) 123 (79-157) 109 (68-143)
Heart rate lowering medication (%) 14 11 11
Lipid lowering medication (%) 10 10 14
Fasting triglycerides (mmol/L) 1.0 (0.7-1.3) 1.0 (0.7-1.5) 1.2 (0.8-1.7)
30 min triglycerides (mmol/L) 1.1 (0.9-1.5) 1.2 (0.9-1.7) 1.4 (1.0-1.9)









HDL cholesterol (mmol/L) 1.6 (0.5) 1.6 (0.5) 1.5 (0.4)
HOMA-IR 0.5 (0.3-0.9) 0.6 (0.3-1.1) 0.8 (0.5-1.4)
Data are expressed as mean (standard deviation), mean (25th-75th percentile) or percentage
Results are based on weighted analyses (n=6174)
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Heart rate and cholesterol
Per 10 beats/min, the total cholesterol concentration was 0.09 mmol/L higher (95% 
CI 0.05, 0.13) (Table 2). After adjustment for confounding factors, including BMI, total 
body fat and HOMA-IR, the difference was 0.06 mmol/L (0.02, 1.10). There was a positive 
association between heart rate and LDL-cholesterol concentration, and an inverse as-
sociation between heart rate and HDL-cholesterol concentration. These associations 
attenuated after adjustment for confounding variables.
Heart rate and triglycerides
Heart rate was associated with fasting serum triglyceride concentration (Table 3). Per 
10 beats/min, fasting serum triglyceride concentration changed with 7.8% (5.4, 10.3). 
After adjustments for confounders this was 5.2% (3.5, 6.9). Heart rate was also associated 
with postprandial serum triglyceride concentrations (30 minutes and 150 minutes after 
a liquid mixed meal) in multivariate analyses. However, when we additionally adjusted 
for fasting serum triglyceride concentration, these results attenuated (Table 3).
Heart rate and intrahepatic triglyceride content
In the NEO study, a random 2354 participants underwent magnetic resonance spec-
troscopy of the liver. After exclusion of missing data on heart rate (40), intrahepatic 
triglyceride content (n=266), education (n=17), physical activity (n=44), HOMA-IR (n=53) 
and other confounders (n=5), the analyses on intrahepatic triglyceride content included 
1929 participants. Included participants were more often male (47%) than excluded par-
ticipants (42%) and had a slightly higher intrahepatic triglyceride content (2.8% (1.4-6.4) 
versus 1.9% (1.1-5.0)). Age and body mass index were not different.







Model 1 Crude 0.09 (0.05, 0.13) −0.02 (−0.03, 0.00) 0.04 (0.01, 0.08)
Model 2 + age, sex 0.06 (0.03, 0.10) −0.04 (−0.06, −0.03) 0.03 (0.00, 0.07)
Model 3 + confounders* 0.08 (0.04, 0.11) −0.04 (−0.05, −0.02) 0.04 (0.01, 0.08)
Model 4 + BMI, TBF 0.07 (0.03, 0.11) −0.01 (−0.02, 0.00) 0.02 (−0.01, 0.06)
Model 5 + HOMA-IR 0.06 (0.02, 0.10) 0.00 (−0.01, 0.02) 0.02 (−0.02, 0.05)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model Assessment Insulin Re-
sistance
Results are based on weighted analyses (n=6174)
Chapter6
108
Heart rate was associated with intrahepatic triglyceride content. Per 10 beats/min, 
intrahepatic triglyceride content changed with 20.3% (13.0, 28.1). Part of this associa-
tion was explained by confounders including BMI, total body fat and HOMA-IR. After all 
adjustments, this difference was 13.1% (7.7, 18.7) per 10 beats/min (Table 4).
Heart rate variability and lipids
Of the 6673 participants included in the NEO study, an Actiheart device was carried 
by 955 participants. In 50 of this 955, the recording failed due to technical problems 
(e.g. broken battery, detached electrodes) or incorrect use by the participant (e.g. 
early removal). From the 905 remaining recordings, we selected 485 recordings with 
maximum quality of IBI data (<1% artefacts) to use for heart rate variability analysis. 
After exclusion of participants with missing data on education (n=5), physical activity 
(n=4), HOMA-IR (n=9) and other confounders (n=2), the present analysis included 465 
Table 3 Percentage difference in triglyceride concentrations per 10 bpm in heart rate
Fasting 30 minutes 150 minutes
Model 1 Crude 7.8 (5.4, 10.3) 6.6 (4.6, 8.7) 5.8 (3.6, 8.0)
Model 2 + age, sex 9.4 (7.0, 11.8) 8.0 (5.9, 10.0) 7.3 (5.2, 9.5)
Model 3 + confounders* 9.5 (7.2, 11.9) 8.1 (6.1, 10.1) 7.4 (5.3, 9.5)
Model 4 + BMI, TBF 7.0 (4.7, 9.3) 6.1 (4.1, 8.0) 5.4 (3.4, 7.5)
Model 5 + HOMA-IR 5.9 (3.9, 8.0) 5.2 (3.5, 6.9) 4.4 (2.6, 6.3)
Model 6 + fasting TG 0.6 (−0.1, 1.2) −0.1 (−1.0, 0.7)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model Assessment Insulin Re-
sistance; TG, triglycerides
Results are based on weighted analyses (n=6174)
Table 4 Percentage difference in intrahepatic triglyceride content per 10 bpm in heart rate
Intrahepatic triglyceride
content
Model 1 Crude 20.3 (13.0, 28.1)
Model 2 + age, sex 22.7 (15.5, 30.4)
Model 3 + confounders* 21.5 (14.5, 29.0)
Model 4 + BMI, TBF 13.5 (7.7, 19.5)
Model 5 + HOMA-IR 13.1 (7.7, 18.7)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication, meal time, alcohol consumption
BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model Assessment Insulin Re-
sistance
Results are based on weighted analyses (n=1929)
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participants. Of this subgroup, 147 participants were also included in the subgroup with 
data on intrahepatic triglyceride content. Included participants were comparable with 
excluded participants, only the percentage men was higher (56% in included versus 
43% in excluded participants).
The associations between heart rate variability parameters and lipid concentrations in 
the circulation were comparable to the associations using heart rate as a determinant. 
Increased heart rate variability (reflecting reduced SNS activity) was associated with 
lower total cholesterol and serum triglyceride concentrations. Unfortunately, due to the 
smaller sample size, these results were all non-significant (Appendix).
DISCUSSION
This is the first study that shows a positive association between activation of the SNS, 
measured by heart rate and heart rate variability, and intrahepatic triglyceride content. 
Furthermore, we identified an association of SNS activity not only with fasting serum 
triglyceride concentrations, but also with serum triglycerides concentrations 30 and 
150 minutes after a standardized mixed meal. Finally, we observed a small positive as-
sociation between heart rate and serum fasting total cholesterol concentrations. The 
positive association of heart rate with LDL-cholesterol, and the inverse association with 
HDL-cholesterol attenuated after adjustment for confounders. The results from this 
study suggest that sympathetic nervous system activity is associated with alterations in 
lipid metabolism.
Studies in rodents clearly indicate as role for the autonomic nervous system in 
lipid metabolism, as vagatomy increases cholesterol concentrations in the circulation, 
whereas sympathectomy decreases cholesterol concentrations.31 However, previ-
ous studies on activation of the SNS and cholesterol concentrations in humans have 
produced conflicting results. We found a positive association of heart rate, reflecting 
SNS activity, with total cholesterol. This has also been shown in some earlier studies.14-16 
We did not find an association of heart rate with LDL-cholesterol and HDL-cholesterol 
after adjustment for confounding variables. This is contradicting some studies,14-16 but 
is in line with another study.32 In line with our results, some earlier studies observed an 
association between activity of the SNS and serum triglyceride concentrations.14, 16, 33 
No study has yet evaluated the association between heart rate and postprandial serum 
triglycerides concentrations 30 and 150 minutes after a liquid mixed meal. We showed 
that heart rate was also associated with postprandial triglyceride concentrations, but 
that this association could be explained by higher fasting triglyceride concentrations 
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with higher heart rate. In addition to cross-sectional studies, one study prospectively 
investigated the relation of heart rate with changes in serum triglyceride and HDL-
cholesterol concentrations over two years.34 An association between heart rate and a 
decrease in HDL-cholesterol concentrations was observed in this study, possibly indicat-
ing that increased SNS activation precedes alterations in lipid metabolism. However, 
no prospective association between heart rate and serum triglycerides concentrations 
was found. Only one previous study investigated the association of SNS activation, mea-
sured as low heart rate variability, with intrahepatic triglyceride content and reported 
lower heart rate variability in individuals with non-alcoholic fatty liver disease compared 
with controls.35 We extend this finding by showing a positive association between heart 
rate and intrahepatic triglyceride content in the general population. Per 10 beats/min 
in heart rate, the difference in intrahepatic triglyceride content was 13.1% (7.7, 18.7), 
independent of confounders including body mass index, total body fat and HOMA-IR.
The most important strength of the present study is the study size of 6174 participants 
with data on lipid concentrations in the circulation. Especially the association of heart 
rate with postprandial serum triglyceride concentrations after a standardized liquid 
mixed meal has not been published yet. Since most individuals are in a postprandial 
state for the larger part of the day, and elevated postprandial serum triglyceride concen-
trations are associated with increased cardiovascular risk, this seems to be an important 
finding.36, 37 Furthermore, intrahepatic triglyceride content measured by MRS, was 
available in 1929 participants. This technique is expensive and time-consuming, and 
therefore usually not available in large cohorts such as the NEO study. A limitation of 
our study is the cross-sectional design which may have resulted in residual confounding 
and reverse causation. Because parameters of SNS activation and lipid concentrations 
were assessed at the same time, we cannot make any statements on the longitudinal 
association between both variables. Furthermore, the absence of the measurement of 
free fatty acids is a limitation. Another limitation of the present study may be that we 
did not measure brown adipose tissue volume present in the body or any markers for 
its activity. Besides an effect on white adipose tissue and the liver, stimulating lipolysis 
and de novo lipogenesis, the SNS also innervates brown adipose tissue. SNS activation 
stimulates the uptake of VLDL-triglycerides in brown adipose tissue for production of 
heat through the mechanism of uncoupling, i.e. non-shivering thermogenesis.38 As a 
result, SNS activation of brown adipose tissue may (partly) counteract the triglyeride-
raising and cholesterol-raising effect of SNS activation of white adipose tissue and liver. 
On the other hand, a divergence of autonomic nervous system activity towards different 
organs has also been proposed, implying that increased SNS activity to white adipose 
tissue or the liver does not necessarily have to be accompanied by increased activity 
towards brown adipose tissue, especially not at room temperature.39
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Stimulation of the SNS seems to be regulated by the hypothalamus, for example by 
release of neuropeptide Y.12 In addition, peripherally produced hormones such as leptin 
and glucagon-like peptide-1 may stimulate the hypothalamus and consequently the 
SNS.40, 41 Activation of the SNS influences lipid metabolism in several ways. Experimental 
studies showed that selective sympathetic denervation of the liver in rats decreased 
both hepatic lipogenesis and decreased hepatic VLDL-triglyceride secretion.12, 13 This 
indicates that SNS activation to the liver stimulates both lipogenesis and the secretion of 
VLDL-triglycerides. Furthermore, in white adipose tissue, stimulation of the SNS induces 
lipolysis, thereby increasing the amount of glycerol and free fatty acids in the circula-
tion.10 Since in a fasting state most triglycerides in the circulation are produced by the 
liver, increased lipogenesis could explain our results on heart rate and the serum fasting 
triglyceride concentration.
On the mechanism underlying the positive association we found between heart rate 
and intrahepatic triglyceride content we can only speculate. In rats, sympathetic hepatic 
denervation or adrenalectomy decreased VLDL-triglyceride production, but increased 
intrahepatic triglyceride content.13 This finding is not in line with our results, that show 
a higher intrahepatic triglyceride content with a higher heart rate. Increased SNS 
activation could possibly induce the accumulation of intrahepatic triglyceride by the 
secretion of leptin and the inhibition of adiponectin. High leptin and low adiponectin 
are associated with both a higher SNS activation and a higher intrahepatic triglyceride 
content.43
Postprandial serum concentrations of triglycerides in the circulation are strongly 
influenced by insulin resistance. Insulin stimulates the expression of lipoprotein lipase 
in adipose tissue, which results in increased uptake and storage of free fatty acids in adi-
pocytes.42 In an insulin resistant state, clearance of lipids from the circulation is therefore 
inhibited. However, in our study we still observed approximately 5% higher postprandial 
serum triglyceride concentrations 30 and 150 minutes after a meal, independent of 
insulin resistance measured as HOMA-IR. This may reflect an association between SNS 
activation and serum postprandial triglyceride concentrations independent of insulin 
resistance. Triglycerides, especially postprandial serum triglycerides concentrations, are 
strongly associated with cardiovascular risk.36, 37 Therefore, elevated postprandial serum 
triglycerides concentrations may be a mechanism underlying the association between 
increased SNS activation and cardiovascular disease.
The strength of the associations of heart rate with cholesterol concentrations is modest. 
The difference in total cholesterol per 10 beats/min was 0.06 mmol/L after adjustments 
for confounders. This difference is clinically irrelevant. The observed associations of 
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heart rate with serum triglyceride concentrations and intrahepatic triglyceride content, 
however, may be of clinical relevance. Per 10 beats/min, fasting triglyceride concentra-
tions were 5.8% higher. For a participant with a fasting triglyceride concentration of 1.0 
mmol/L, this would imply an additional 0.06 mmol/L, independent of all confounding 
variables. The difference in intrahepatic triglyceride content was 13.1% per 10 beats/min 
in heart rate. In a participant with 5% intrahepatic triglycerides, this would correspond 
to 0.7% more liver fat.
In conclusion, SNS activation, measured as higher resting heart rate or lower heart rate 
variability, was associated with higher fasting total cholesterol, higher fasting and post-
prandial serum triglyceride concentrations, and with higher intrahepatic triglyceride 
content. These results imply that the SNS is involved in lipid metabolism in humans, 
and that dyslipidaemia may be targeted by lowering SNS activation. Future research 
should elucidate whether abnormalities in lipid profile are a mechanism underlying the 
association between SNS activation and cardiovascular disease.
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Model 1 Crude −0.02 (−0.14, 0.09) 0.00 (−0.06, 0.06)) 0.01 (−0.11, 0.13)
Model 2 + age, sex 0.05 (−0.09, 0.18) 0.04 (−0.02, 0.10) 0.06 (−0.06, 0.19)
Model 3 + confounders* 0.07 (−0.06, 0.20) 0.03 (−0.02, 0.09) 0.08 (−0.05, 0.20)
Model 4 + BMI, TBF 0.08 (−0.05, 0.20) 0.02 (−0.03, 0.07) 0.09 (−0.03, 0.21)
Model 5 + HOMA-IR 0.09 (−0.04, 0.21) 0.00 (−0.05, 0.06) 0.10 (−0.03, 0.22)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
SDNN, standard deviation of all normal intervals; BMI, body mass index; TBF, total body fat; HOMA-IR, up-
dated Homeostasis Model Assessment Insulin Resistance
Results are based on weighted analyses (n=465)







Model 1 Crude −2.9 (−11.3, 4.9) −2.7 (−9.9, 4.0) −2.4 (−9.6, 4.3)
Model 2 + age, sex −5.6 (−14.9, 2.9) −4.8 (−12.6, 2.5) −4.3 (−11.7, 2.7)
Model 3 + confounders* −4.4 (−12.9, 3.5) −4.2 (−11.5, 2.6) −4.5 (−11.4, 2.0)
Model 4 + BMI, TBF −3.7 (−12.1, 4.0) −3.6 (−10.7, 3.1) −3.9 (−10.6, −2.5)
Model 5 + HOMA-IR 5.9 (3.9, 8.0) −0.8 (−6.5, 4.5) −1.7 (−7.3, 3.5)
Model 6 + fasting TG −0.8 (−2.6, 1.0) −1.1 (−4.2, −1.9)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
SDNN, standard deviation of all normal intervals; BMI, body mass index; TBF, total body fat; HOMA-IR, up-
dated Homeostasis Model Assessment Insulin Resistance; TG, triglycerides
Results are based on weighted analyses (n=465)







Model 1 Crude −0.11 (−0.22, 0.00) 0.01 (−0.04, 0.06) −0.07 (−0.18, 0.04)
Model 2 + age, sex −0.10 (−0.22, 0.02) 0.01 (−0.05, 0.06) −0.06 (−0.17, 0.06)
Model 3 + confounders* −0.07 (−0.17, 0.04) 0.01 (−0.03, 0.06) −0.02 (−0.13, 0.09)
Model 4 + BMI, TBF −0.06 (−0.17, 0.05) 0.01 (−0.04, 0.05) −0.02 (−0.12, 0.09)
Model 5 + HOMA-IR −0.05 (−0.16, 0.06) −0.01 (−0.06, 0.03) −0.01 (−0.11, 0.10)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
RMSSD, root mean square of the successive differences; BMI, body mass index; TBF, total body fat; HOMA-IR, 
updated Homeostasis Model Assessment Insulin Resistance
Results are based on weighted analyses (n=465)
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Model 1 Crude −5.8 (−13.6, 1.4) −5.4 (−12.2, 0.9) −4.8 (−11.0, 1.0)
Model 2 + age, sex −5.6 (−13.9, 2.1) −5.2 (−12.4, 1.6) −4.4 (−11.0, 1.9)
Model 3 + confounders* −5.6 (−13.8, 2.0) −5.5 (−12.6, 1.3) −4.8 (−11.7, 1.6)
Model 4 + BMI, TBF −5.8 (−13.8, 1.6) −5.6 (−12.5, 0.8) −4.9 (−11.5, 1.4)
Model 5 + HOMA-IR −2.2 (−7.3, 2.6) −2.7 (−7.4, 1.9) −1.7 (−6.4, 2.8)
Model 6 + fasting TG −0.7 (−2.3, 0.8) 0.3 (−2.3, 3.0)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
RMSSD, root mean square of the successive differences; BMI, body mass index; TBF, total body fat; HOMA-IR, 
updated Homeostasis Model Assessment Insulin Resistance; TG, triglycerides
Results are based on weighted analyses (n=465)







Model 1 Crude −0.02 (−0.14, 0.09) 0.01 (−0.04, 0.06) −0.01 (−0.12, 0.10)
Model 2 + age, sex 0.06 (−0.08, 0.20) 0.06 (0.00, 0.12) 0.05 (−0.07, 0.18)
Model 3 + confounders* 0.07 (−0.07, 0.21) 0.05 (−0.01, 0.10) 0.06 (−0.07, 0.18)
Model 4 + BMI, TBF 0.08 (−0.06, 0.21) 0.03 (−0.03, 0.08) 0.07 (−0.06, 0.19)
Model 5 + HOMA-IR 0.09 (−0.05, 0.22) 0.01 (−0.04, 0.06) 0.08 (−0.05, 0.20)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
LF, low frequency; BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model Assess-
ment Insulin Resistance
Results are based on weighted analyses (n=465)







Model 1 Crude −4.2 (−11.1, 2.2) −4.1 (−10.8, 2.3) −4.3 (−11.1, 2.0)
Model 2 + age, sex −7.6 (−15.7, −0.1) −6.6 (−14.1, 0.5) −6.5 (−14.0, 0.5)
Model 3 + confounders* −5.5 (−13.3, 1.7) −5.0 (−12.1, 1.7) −6.1 (−13.4, 0.7)
Model 4 + BMI, TBF −5.1 (−13.0, 2.2) −4.6 (−11.7, 2.0) −5.8 (−13.1, 1.1)
Model 5 + HOMA-IR 0.6 (−5.2, 6.7) −0.3 (−5.9, 5.1) −2.5 (−3.4, 7.9)
Model 6 + fasting TG −0.7 (−2.6, 1.1) −2.4 (−5.9, 1.0)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
LF, low frequency; BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model Assess-
ment Insulin Resistance; TG, triglycerides
Results are based on weighted analyses (n=465)
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Model 1 Crude −0.06 (−0.17, 0.05) 0.03 (−0.02, 0.09) −0.06 (−0.17, 0.05)
Model 2 + age, sex −0.08 (−0.21, 0.04) 0.01 (−0.05, 0.06) −0.06 (−0.17, 0.06)
Model 3 + confounders* −0.04 (−0.16, 0.08) 0.01 (−0.04, 0.07) −0.02 (−0.13, 0.09)
Model 4 + BMI, TBF −0.04 (−0.16, 0.08) 0.01 (−0.04, 0.06) −0.02 (−0.13, 0.09)
Model 5 + HOMA-IR −0.03 (−0.15, 0.09) −0.01 (−0.05, 0.04) −0.01 (−0.12, 0.10)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
HF, high frequency; BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model As-
sessment Insulin Resistance
Results are based on weighted analyses (n=465)







Model 1 Crude −6.7 (−14.2, 0.3) −6.3 (−13.1, 0.0) −6.3 (−13.1, 0.0)
Model 2 + age, sex −4.9 (−12.8, 2.5) −4.7 (−11.9, 2.0) −4.4 (−11.5, 2.3)
Model 3 + confounders* −4.6 (−12.7, 2.8) −4.8 (−12.1, 1.9) −4.6 (−12.1, 2.4)
Model 4 + BMI, TBF −5.4 (−13.4, −2.0) −5.6 (−12.7, 1.0) −5.2 (−12.6, 1.7)
Model 5 + HOMA-IR −0.7 (−6.4, 4.6) −1.5 (−6.7, 3.4) −1.6 (−7.4, 3.9)
Model 6 + fasting TG −0.9 (−2.3, 0.6) −0.9 (−4.3, 2.4)
*Confounders: smoking, education, physical activity, heart rate lowering medication and lipid lowering 
medication
HF, high frequency; BMI, body mass index; TBF, total body fat; HOMA-IR, updated Homeostasis Model As-
sessment Insulin Resistance; TG, triglycerides
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The main objective of this thesis was to study the role of ANS function in the develop-
ment of diabetes and cardiovascular disease. Based on earlier studies it has remained 
unclear whether impaired ANS function is a risk factor for the development of diabetes 
and cardiovascular disease, or merely a consequence of pre-existing disease. By using an 
epidemiological approach, this thesis showed that an impaired ANS function increased 
the risk of cardiovascular disease, but was not a risk factor for the occurrence of diabetes. 
In this discussion section we summarize our main results and discuss methodological 
considerations and possible implications of our findings.
MAIN FINDINGS
Obesity
In chapter 2 we showed that body fat, in particular visceral fat, was associated with 
established and novel measures of activation of the sympathetic nervous system (heart 
rate, QTc and the ventricular gradient magnitude) in non-diabetic participants with 
structurally normal hearts. Our study expands results from previous studies on the 
association between body fat and ANS function by showing that visceral fat may be 
the most important fat depot for activation of the sympathetic nervous system.1-3 These 
findings may be explained by the higher secretion rate of pro-inflammatory cytokines 
of visceral fat than of subcutaneous fat.4-7 These cytokines can either directly stimulate 
the central nervous system, by crossing the blood-brain-barrier, or induce low-grade 
inflammations, resulting in sympathetic activation.8, 9
It must be noted, however, that our cross-sectional study does not permit conclusions 
on the direction of associations. Because body fat and sympathetic activation were 
measured at the same time, we cannot exclude the possibility that sympathetic ner-
vous system activation may lead to visceral fat accumulation. However, our hypothesis 
that body fat influences sympathetic activation is supported by previous research that 
showed that a decrease in the amount of body fat by a hypocaloric diet or exercise 
attenuated sympathetic activation.10-16 Because visceral fat is strongly associated with 
cardiovascular risk17-20, our results suggest that activation of the sympathetic nervous 
system may be a mechanism underlying the association between visceral fat and car-
diovascular disease.
Insulin resistance and type 2 diabetes mellitus
In chapter 3 we showed that ANS function was not associated with incident type 2 
diabetes mellitus in a prospective cohort study with 9.2 years of follow-up. Our study 
must be interpreted together with six previous studies that prospectively investigated 
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the association between ANS function and incident diabetes.21-26 Two studies reported 
an association between resting heart rate and incident diabetes.21, 22 However, these 
results were not adjusted for glucose or insulin concentrations at baseline and there-
fore impairments in glucose metabolism may have influenced ANS function. Another 
study reported an increased risk of mortality due to diabetes, but no increased risk of 
non-fatal diabetes.23 This may suggest that impaired ANS function is associated with 
mortality in general instead of the development of diabetes. Two studies observed an 
association between impaired ANS function and incident diabetes only in subgroups of 
their population.24, 25 In de CARDIA study, slow heart rate recovery was associated with 
diabetes in participants with poor fitness.24 After stratification of our data on level of 
fitness, we could not replicate this finding. Possibly, fitness is an effect modifier only in 
a young population. The population of the CARDIA study was much younger than the 
population of the Hoorn study (18-30 years versus 50-75 years). The Australian Diabetes 
Obesity and Lifestyle study showed that higher heart rate was a risk factor for diabetes 
mainly in non-obese men.25 However, the reference category in this analysis was chosen 
as <60 beats/min and the risk of diabetes was similar in the heart rate categories 60-70, 
80-90 and >80 beats/min. Normal values for heart rate are defined as 60-80 beats/min. 
Possibly, individuals with a heart rate below 60 beats/min represented a specific group 
in this study with a low risk of disease, for example young athletes. Because the risk of 
diabetes was similar in all other categories of heart rate, the reference category may 
have strongly influenced the results and overestimated the association between heart 
rate and incident diabetes. Finally, one study reported an association between heart 
rate and incident diabetes (relative risk per SD (9.7 beats/min) = 1.06 (95%CI 1.00, 1.13). 
However, no associations were observed for parameters of heart rate variability.26 Hence, 
taking our study and all the above described results together, there does not seem to 
be a large body of evidence for a causal role of the ANS in the development diabetes.
Several previous cross-sectional studies observed associations between impaired ANS 
function and impaired glucose metabolism.27-31 The results from chapter 3 suggest that 
these associations may reflect reverse causation, and that impaired ANS function is 
more likely a consequence of impaired glucose metabolism than a risk factor for type 2 
diabetes. In chapter 4 we hypothesized insulin resistance to be a mechanism underlying 
the association between body fat and ANS function. We showed (in line with chapter 2) 
that body fat was associated with ANS function measured as heart rate variability, and 
furthermore we showed that insulin resistance for a large part mediated the association 
between body fat and ANS function. Even though the latter results are based on cross-
sectional data, our findings from chapter 3 and 4 together support the existence of a 
pathophysiological mechanism in which insulin resistance or type 2 diabetes precedes 
impairment of the ANS.
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Cardiovascular disease
In chapter 5 we aimed to summarize the evidence on the association between ANS 
function and incident cardiovascular disease using meta-analysis and meta-regression. 
We investigated heart rate variability, divided in percentiles, as a risk factor for a first 
fatal or non-fatal cardiovascular event in populations without prevalent cardiovascular 
disease. Based on the nine cohort studies with a total of 21988 participants included in 
our analysis, persons in the lowest percentile of heart rate variability had a 32 to 45% 
increased risk of a first cardiovascular event, depending on the measure of heart rate 
variability. Hence, by studying incident cardiovascular disease in a population without 
previous events, we showed in this chapter that impaired ANS function may be involved 
in the development cardiovascular disease.
Subsequently, we hypothesized that impaired lipid metabolism may be a mechanism un-
derlying the association between ANS function and the development of cardiovascular 
disease. Therefore, we studied the associations between activation of the sympathetic 
nervous system and lipid concentrations in both the circulation and the liver. Chapter 
6 showed that resting heart rate was positively associated with both fasting and post-
prandial serum triglyceride concentrations. Per 10 beats/min, fasting serum triglycerides 
were 5.9% (95% CI: 3.9, 7.8) higher. We were the first to investigate associations of ANS 
function with postprandial serum triglycerides and intrahepatic triglyceride content. We 
showed that postprandial triglycerides were 5.2% (3.5, 6.9) higher 30 minutes after the 
mixed meal, and 4.4% (2.6, 6.3) higher 150 minutes after the mixed meal. Furthermore, 
per 10 beats/min of resting heart rate, intrahepatic triglyceride content was 13.1% (7.7, 
18.7) higher. Although this study was cross-sectional, the results are supported by ex-
perimental studies that show that invasive sympathetic denervation in rats is followed by 
abnormal lipid concentrations.32, 33 It is furthermore well-established that dyslipidaemia, 
especially a high serum triglyceride concentration34, 35, is associated with an increased 
risk of cardiovascular disease. Therefore, our results may imply that impaired ANS func-
tion increases cardiovascular risk by alterations in the lipid metabolism.
METHODOLOGICAL CONSIDERATIONS
Making causal inferences on the basis of observational studies is often challenging, 
because several sources of bias must be taken into account. In this thesis we used an 
epidemiological approach to diminish the effects of bias on our results. In the next 
paragraphs, limitations to the measurement of ANS function, residual confounding, loss 
to follow up and reverse causation are considered.
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Interpretation of and limitations to the measurement of ANS function in this 
thesis
In this thesis, we used several measures of ANS function: resting heart rate, heart rate 
variability, baroreflex sensitivity, Ewing tests and electrocardiographic measures of 
sympathetic activation.
Heart rate, heart rate variability and baroreflex sensitivity are commonly used, non-
invasive measures that reflect mixed sympathetic and parasympathetic outflow. In the 
interpretation of heart rate variability it is important to take the difference between 
autonomic tone and modulation in parasympathetic or sympathetic outflow into ac-
count. Heart rate variability does not correspond to parasympathetic or sympathetic 
tone (as does resting heart rate), but to modulations in efferent activity.36, 37 Therefore, 
an increased high frequency spectral component of heart rate variability indicates 
increased modulation of parasympathetic activity, but not necessarily an increased 
parasympathetic tone. Parasympathetic modulation can be reduced when parasym-
pathetic tone is abolished or when the parasympathetic nervous system is constantly 
stimulated, two very different scenarios. Constant stimulation of parasympathetic tone 
will decrease heart rate, but will also result in decreased high frequency power heart 
rate variability because there is no modulation in parasympathetic outflow.38 Similarly, 
the low frequency spectral component also does not provide information about the 
sympathetic tone, but of modulation in sympathetic outflow.39 Heart rate and heart 
rate variability therefore reflect different aspects of the ANS. Heart rate is indicative 
of autonomic tone, whereas heart rate variability is a manifestation of activity of the 
baroreflex, which purpose is to buffer blood pressure by adaptions in sympathetic and 
parasympathetic outflow.39-41 Both an increased resting heart rate and decreased heart 
rate variability reflect impairment of the ANS.
In this thesis, heart rate variability was measured during spontaneous breathing. In 
spectral heart rate variability analysis, the high frequency peak of the spectrum can be 
attributed to respiration. However, when breathing is low frequent (6 breaths/minute), 
the respiration peak shifts to lower frequencies and thereby (partly) overlaps with the 
smaller low frequency peak that is caused by a blood pressure resonance phenomenon 
mediated by the baroreflexes. This will result in increased low frequency heart rate 
variability and an overestimation of the baroreflex sensitivity.42 Because we mainly used 
free breathing recordings to estimate ANS function, we cannot exclude the possibility 
that our measurements are affected by slow breathing of our participants. Such random 
error in the measurement of heart rate variability may have diluted the observed as-
sociations in our studies. However, most individuals will have a respiration that is at high 
frequency (normal range 12-18/min) and therefore the influence of slow breathing is 
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probably limited in this thesis. Only in chapter 3, baroreflex sensitivity was systemati-
cally measured using deep breathing recordings. In this chapter, the sensitivity of the 
baroreflex is overestimated in all individuals and must be interpreted with care. Because 
other measures of ANS function showed similar associations with incident diabetes in 
this chapter, the deep breathing does not affect our conclusions.
A limitation of the measurement of ANS function in chapter 2 may be the use of 
novel electrocardiographic measures of sympathetic activation, identified by three 
experimental studies in which the sympathetic nervous system was stimulated me-
chanically or pharmacologically.43-45 The validity and reproducibility of some of these 
measures (e.g., the ventricular gradient or spatial QRS-T angle) is yet unknown and 
should be established in future studies. However, the results of these novel measures 
were similar to the results of well-known measures of ANS function (heart rate, heart 
rate variability) studied in this chapter. This indicates that the results of chapter 2 are 
robust and may provide a first step towards the validation of these novel measures.
Residual confounding by physical activity and mental stress
All studies in this thesis are based on observational data and we aimed to adjust for 
all known and measured confounding variables. However, residual confounding may 
still be present when not all confounding variables are known or measured, or when 
there is measurement error in the confounding variables. In chapter 5 we performed 
a meta-analysis and meta-regression. The nine included studies were adjusted for a 
varying range of confounding variables. However, none of the studies were adjusted 
for physical activity and mental stress. Because low physical activity and mental stress 
may impair ANS function and increase the risk of cardiovascular disease, there may have 
been residual confounding. This may have resulted in an overestimation of the true as-
sociation between ANS function and the development of cardiovascular disease. The 
associations studied in chapters 4 and 6 may also suffer from residual confounding by 
mental stress. In chapter 4 we performed a mediation analysis. Mental stress may have 
been a residual confounding variable because it influences insulin resistance (the medi-
ating variable) and autonomic nervous system function (the outcome). Not adjusting for 
a variable that may confound the association between the mediator and the outcome 
may result in an overestimation of the mediated effect. In case of residual confounding 
by mental stress, the association between body fat and autonomic nervous system func-
tion that is mediated by insulin resistance, may therefore have been overestimated. In 
chapter 6 we investigated the association between ANS function and lipid metabolism. 
Because mental stress may also influence lipid concentrations, any residual confounding 
may have resulted in an overestimation of the true association. Hence, it is a limitation of 
these studies that we could not adjust for physical activity and mental stress. In addition, 
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because of the observational nature of our studies we cannot exclude residual confound-
ing by unknown factors or measurement error in our confounding variables. However, it 
is unlikely that these factors were completely responsible for the observed associations. 
Furthermore, because our studies were adjusted for many confounders that are strongly 
correlated with the potential confounding variables physical activity and mental stress, 
such as age, sex, and body mass index, it is unlikely that any overestimation of the true 
associations would have been large.
Loss to follow up in cohort studies
In cohort studies, selection bias may occur when reasons for loss to follow-up are related 
to prognosis (informative censoring). The consequence of such bias is that the associa-
tion between exposure and outcome among those selected for analysis differs from the 
association among those eligible.46, 47 In the Hoorn study (chapter 3), 140 of the 438 
participants at baseline did not participate in the follow-up investigation. Reasons for 
non-participation were death (n=51), moving to another region (n=29) or unknown 
(n=59). Participants included in our analyses appeared overall healthier at baseline than 
those who were lost to follow up. If the association between ANS function and type 2 
diabetes mellitus among non-participants had been stronger than among participants, 
this would have led to an underestimation of the true association in our analyses. We 
performed a sensitivity analysis to investigate the potential effect of such selection bias. 
When we analysed a hypothetical “worst case scenario” of the complete population in 
which all the participants who did not participate in the follow-up investigation would 
have developed type 2 diabetes mellitus, there was still no association between ANS 
function and the incidence of diabetes. Selection bias due to differential loss to follow-
up may also have played a role in chapter 5, because in two studies that were included 
in our meta-analysis, the percentage of participants loss to follow-up was unknown. 
However, in the other seven included studies, the percentage of loss to follow-up was 
small (≤ 5.6%) and therefore selection bias due to informative censoring could not have 
strongly influenced our results.
Reverse causation
Reverse causation may occur especially in cross-sectional studies. When the exposure 
and outcome variables are measured at the same time, the observed exposure may 
be a consequence of the outcome variable rather than a cause. In longitudinal studies 
reverse causation may also play a role when the outcome or disease of interest is already 
(subclinically) prevalent at baseline.
The results from chapters 2 and 6 were based on cross-sectional analyses. Therefore, 
we cannot exclude the possibility that impaired ANS function has led to accumulation 
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of visceral fat, or that alterations in lipid metabolism have led to impaired ANS func-
tion, instead of vice versa. In these chapters we have to rely on current literature and 
experimental studies that support our hypothesized directions and conclusions that 
visceral fat most likely leads to impaired ANS function, whereas impaired ANS function 
may result in alterations in lipid metabolism.
In chapters 3 and 5, we studied associations of ANS function with incident diabetes 
and cardiovascular disease using prospective follow-up studies. By studying first events 
of diabetes and cardiovascular disease during follow-up of individuals without pre-
existing disease at baseline, we minimized a potential influence of underlying disease 
and showed that impaired ASN function is a risk factor for cardiovascular disease, but 
not for type 2 diabetes.
CONCLUSIONS AND IMPLICATIONS
Despite the methodological challenges mentioned above, our results contributed to the 
unravelling of causal pathways between obesity, diabetes and cardiovascular disease. 
On the basis of the results from this thesis and the literature, the Figure shows the puta-
tive pathways between body fat, insulin resistance and diabetes, ANS function, lipid 
metabolism and cardiovascular disease.
The main conclusions of this thesis are that excess body fat, in particular visceral fat, 
is associated with activation of the sympathetic nervous system in individuals without 
diabetes and cardiovascular disease. Furthermore, this thesis showed that impaired ANS 
function is not a risk factor for the development of diabetes mellitus. The presented stud-
ies suggest that insulin resistance precedes the impairment of the ANS. This implies that 
impaired ANS function is merely a consequence of diabetes, and that insulin resistance 
may be a mechanism underlying the association between body fat and ANS function. 
Therefore, ANS function does not seem useful in the prevention of diabetes and this 
thesis emphasizes the importance of controlling of body weight and glycaemic status in 
the prevention of the development of diabetes. However, our research does imply that 
the ANS is affected by insulin resistance before the onset of diabetes. This may in part 
explain the increased risk of cardiovascular disease in insulin resistant individuals.48-50
The results from this thesis also show that impaired ANS function is a risk factor for the 
development of cardiovascular disease in populations without pre-existing cardiovascu-
lar disease. Furthermore, individuals with a higher heart rate have higher concentrations 
of cholesterol and triglycerides in the circulation and a higher intrahepatic triglyceride 
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content, suggesting that an altered lipid metabolism may be a mechanism underlying 
the association between ANS function and cardiovascular disease. Because ANS func-
tion is a risk factor for the development of cardiovascular disease, the ANS may be a 
target in the prevention of cardiovascular disease, or may be used to identify individuals 
at high risk of cardiovascular disease. Enhancing the ANS function may be useful in 
the treatment of dyslipidaemia and the prevention of a first cardiovascular event. Beta 
blockers are well-known drugs that decrease the effect of sympathetic neurotransmit-
ters on β-sympathetic receptors. However, these drugs have many side effects and are 
therefore unlikely to play a role in the primary prevention of cardiovascular disease in 
otherwise healthy individuals. Both observational studies and randomized controlled 
trials have shown that a hypocaloric diet and exercise training improve the function of 
the ANS and inhibit sympathetic activation.10-16 Lifestyle modifications may provide the 
best intervention to preserve the function of the ANS. Therefore, the results of this thesis 
emphasize the maintenance of a healthy body weight as the cornerstone in the preven-
tion of diabetes and cardiovascular disease. Future studies should further elucidate the 
role of the ANS in the causal pathways between body fat, cardiovascular risk factors 
and cardiovascular endpoints. The ongoing collection of long-term follow-up data in 
participants of the NEO study will contribute to this in the near future.
Autonomic nervous 
system function







Ch 2 Ch 5
Ch 6Ch 4 Ch 3/4
Figure. Hypothetical pathways between body fat, insulin resistance and diabetes, autonomic nervous sys-
tem function, lipid metabolism and cardiovascular disease
Directional arrows indicate the flow of association. Confounding variables include age, sex, smoking status, 
social economic status, physical activity, mental stress→ : results from this thesis; Ch=chapter⇢ : evidence from literature
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Het autonome zenuwstelsel (AZS) reguleert de functie van organen en is belangrijk 
voor homeostase, het in evenwicht houden van het interne milieu van het lichaam. Het 
AZS wordt niet bewust aangestuurd, maar ontvangt informatie van onder andere de 
hersenen, de circulatie, de zintuigen en het limbisch systeem en vertaalt dit in uitgaande 
signalen. Deze signalen worden doorgegeven aan de rest van het lichaam door de twee 
takken van het autonome zenuwstelsel, het parasympathische en sympathische zenuw-
stelsel. Het parasympathische zenuwstelsel is vooral actief in rust, en zorgt onder andere 
voor een rustige hartslag en een actieve spijsvertering. Het sympathische zenuwstelsel 
is vooral actief tijdens perioden van activiteit, zoals lichamelijk inspanning of emo-
tionele momenten. In gezonde mensen is er veel modulatie in parasympathische en 
sympathische signalen, afhankelijk van wat het lichaam nodig heeft, en deze modulatie 
is een teken dat het lichaam zich goed kan aanpassen. Als de werking van het autonoom 
zenuwstelsel verminderd is, is er minder modulatie en is het sympathisch zenuwstelsel 
dominant. Het is bekend dat mensen met obesitas, diabetes of hart- en vaatziekten vaak 
een slechtere AZS-functie hebben. Echter, het is onduidelijk of een slechtere AZS-functie 
alleen een gevolg is van diabetes en hart- en vaatziekten, of dat het AZS ook betrokken 
is bij het ontstaan van deze ziekten. Het doel van dit proefschrift was dan ook om te 
onderzoeken of AZS-functie een rol speelt in het ontstaan van diabetes en hart- en 
vaatziekten.
LICHAAMSVET
Oorspronkelijk werd gedacht dat weinig activiteit van het sympathische zenuwstelsel 
zou leiden tot de opslag van lichaamsvet. Tegenwoordig lijkt het echter waarschijnlijker 
dat een hoge activiteit van het sympathische zenuwstelsel en een lage activiteit van het 
parasympathische zenuwstelsel een rol spelen in het ontstaan van een overmaat aan 
lichaamsvet en ziekte. De resultaten van hoofdstuk 2 sluiten aan bij deze hypothese. 
Dit hoofdstuk beschrijft het verband tussen verschillende maten van lichaamsvet en 
activiteit van het sympathische zenuwstelsel. De resultaten laten zien dat de hoeveel-
heid lichaamsvet, in het bijzonder visceraal vet (vet dat is opgeslagen rond de organen 
in de buik), samenhangt met activatie van het sympathische zenuwstelsel. Omdat een 
ziektegeschiedenis van diabetes en hart- en vaatziekten veel invloed heeft op het auto-
nome zenuwstelsel, zijn in dit onderzoek alle mensen met diabetes of afwijkingen aan 
het hart uitgesloten van de analyse. De resultaten suggereren daarom dat lichaamsvet 
al invloed heeft op de activiteit van het sympathische zenuwstelsel vóórdat ziekten op-
treden. Een verklaring hiervoor zou kunnen zijn dat hormonen en inflammatoire stoffen 
die door vetcellen worden uitgescheiden mogelijk het sympathische zenuwstel kunnen 




effect heeft op het ontstaan van hart- en vaatziekten door het beïnvloeden van de 
activiteit van het sympathische zenuwstelsel.
INSULINERESISTENTIE EN DIABETES
Een slechtere functie van het AZS is een bekende complicatie van type 2 diabetes mel-
litus. Verschillende onderzoeken hebben laten zien dat insulineresistentie (preklinische 
diabetes) samenhangt met de functie van het AZS. Het is echter onbekend of de AZS-
functie een oorzaak is van het ontstaan van diabetes. In hoofdstuk 3 zijn gegevens 
van de Hoorn studie gebruikt om deze vraag te beantwoorden. De resultaten laten zien 
dat de functie van het AZS geen invloed heeft op het ontstaan van de diabetes. Op 
basis van de resultaten van hoofdstuk 3 lijkt het waarschijnlijker dat de aanwezigheid 
van insulineresistentie het AZS beïnvloedt, dan andersom. In hoofdstuk 4 borduren we 
verder op de resultaten van hoofdstuk 2 en 3 met als hypothese dat lichaamsvet de 
functie van het AZS beïnvloedt door bij te dragen aan een insulineresistente staat van 
het lichaam. De resultaten wijzen er inderdaad op dat insulineresistentie gedeeltelijk 
het verband tussen lichaamsvet en AZS functie verklaart.
HART- EN VAATZIEKTEN
Het is bekend dat bij mensen met hart- en vaatziekten een slechtere functie van het AZS 
samenhangt met een slechtere prognose en meer sterfte. Het doel van hoofdstuk 5 was 
om te onderzoeken of een slechtere AZS-functie ook een risicofactor is voor het ontstaan 
van hart- en vaatziekten in de algemene bevolking. Dit hoofdstuk is een meta-analyse 
waarin alle literatuur naar het verband tussen variabiliteit in hartslag en het ontstaan 
van hart- en vaatziekten is samengevat. Negen onderzoeken, waarin de functie van 
het AZS was gemeten als hartslagvariabiliteit, bleken geschikt voor deze meta-analyse. 
Afhankelijk van de gebruikte maat voor hartslagvariabiliteit hadden mensen met een 
slechtere functie van het AZS een 32 tot 45% hoger risico op het ontwikkelen van hart- 
en vaatziekten dan mensen met een betere functie van het AZS.
Een belangrijke vraag die tot op heden nog niet beantwoord kan worden, is hoe een 
slechtere functie van het AZS het risico op hart- en vaatziekten verhoogt. Uit de resultaten 
van hoofdstuk 6 blijkt dat de functie van het AZS samenhangt met de concentratie van 
vetten in het bloed en in de lever. Deze resultaten suggereren dat een slechtere functie 
van het AZS mogelijk een verhogend effect heeft op de concentraties vetten in bloed en 





De belangrijkste conclusies van dit proefschrift zijn dat overmatig lichaamsvet, vooral 
vet in de buik, samenhangt met activatie van het sympathische zenuwstelsel in mensen 
zonder diabetes of hart- en vaatziekten. Daarnaast laat dit proefschrift zien dat een 
slechtere functie van het AZS geen risicofactor is voor het ontstaan van diabetes. Uit 
de resultaten blijkt wel dat veel lichaamsvet mogelijk bijdraagt aan het ontstaan van 
insulineresistentie, waardoor de functie van het AZS zou kunnen verminderen. Dit 
proefschrift suggereert ook dat het AZS beïnvloed wordt door insulineresistentie vóór 
het ontstaan van diabetes. Mogelijk is dit een verklaring voor het verhoogde cardiovas-
culaire risico bij mensen met insulineresistentie. De resultaten van dit proefschrift tonen 
aan dat een slechtere functie van het AZS ook een risicofactor is voor het ontstaan van 
hart- en vaatziekten bij mensen zonder eerdere hart- en vaatziekten. De functie van het 
AZS hangt samen met de concentratie vetten in het bloed en in de lever, en mogelijk is 
een verandering in vetstofwisseling een verklaring voor het verband tussen AZS functie 
en hart- en vaatziekten.
Aangezien AZS-functie een risicofactor is voor hart- en vaatziekten, zou het gebruikt 
kunnen worden als aangrijpingspunt om mensen met een hoog risico te identificeren, 
en bij het voorkómen van hart- en vaatziekten. Wellicht zou het verbeteren van de 
AZS-functie hart- en vaatziekten kunnen voorkómen. Een groep van medicijnen die de 
activiteit van het sympathisch zenuwstelsel remt zijn bètablokkers. Helaas hebben deze 
medicijnen veel bijwerkingen en zijn daarom minder geschikt voor primaire preventie 
in mensen zonder gezondheidsklachten. Uit eerdere interventiestudies blijkt dat een 
gezond leefpatroon met voldoende beweging en een gezond voedingspatroon de 
functie van het AZS kan verbeteren. Dit proefschrift benadrukt daarom dat, op dit mo-
ment, een gezond gewicht het belangrijkste uitgangspunt is voor het voorkómen van 
hart- en vaatziekten. Toekomstige studies zijn nodig om de rol van AZS in de oorzake-
lijke verbanden tussen lichaamsvet, cardiovasculaire risicofactoren en cardiovasculaire 
eindpunten te ontrafelen. De continue verzameling van gegevens en analyse van het 
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